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ABSTRACT 
Diabetes is a serious condition that affects all the body’s systems including kidneys, 
heart, eyes and limbs. This alone makes type II diabetes a life threatening disease; an 
expensive disease and economic burden that many individuals struggle to cope with. 
 
The rapid growth type II diabetes in South Africa is associated with the change of life 
style, and environmental factors brought by westernized way of life living in rural 
areas. Despite the technical advances in diagnosis and therapy of diabetes many 
people still use alternative forms of therapy due to the cost, traditional reasons and 
religion. Some of the people use the conventional medication together with the 
alternative therapy without informing their doctor and knowing the pathological 
changes. 
 
The aim of the study was to investigate pathological changes in male Wistar rats after 
co-treatment of type II diabetes with metformin and Sutherlandia frutescens and the 
possible synergistic and antagonistic effects. The thirty five rats were divided into five 
groups, seven in each group.  There were two control groups and three test groups. 
Only the first control group was on a low fat diet (normal rat pellets) and second control 
group and test groups were on a high fat diet which induces obesity, insulin resistance 
and leads a typical prediabetic state for 12 weeks (Buettner et al., 2006). After 11.5 
weeks medication was administered by oral gavaging to the test groups for 4 weeks and 
control groups received water. 
 
Blood was collected for determination of glucose, insulin, lipid profile and the 
concentrations of the liver enzymes. Pancreas, liver and kidney tissue were removed 
and used for histology. Urine was collected from the bladder for creatinine analyses. 
 
The plant + metformin group co-treatment was better in managing hyperglycemia, liver 
damages were minimal and also weight control was better when compared to metformin 
alone. 
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                   CHAPTER 1 
 
   LITERATURE REVIEW 
 
Diabetes mellitus is a common chronic disorder and represents a serious 
health challenge.  It greatly increases the risk of coronary heart disease and 
stroke, and is a leading cause of blindness, kidney failure and limb 
amputations (Joshi & Joshi, 2009). The prevalence of diabetes is on the 
increase, and an estimated 239 million people world people-wide are 
expected to have the condition by the year 2020 (Patel, 2003).It is a systemic 
metabolic disorder characterized by a tendency to chronic hyperglycaemia 
with disturbances in carbohydrate, fat, and protein metabolism that arises 
from a defect in insulin secretion, insulin action or both (Marshall & Bangert, 
2008). It can be divided into 4 categories namely type I diabetes (insulin 
dependent diabetes mellitus), type II diabetes (non –insulin dependent 
diabetes), gestational diabetes mellitus and other specific types of diabetes 
(Bishop, Fody, & Schoeff, 2010). 
 
Type II diabetes mellitus is the most common form of diabetes worldwide 
affecting 4% the population (Horikawa, Oda, Cox, Li, Orho-Melander, Hara, 
……Bell, 2000). It is multifactorial in origin with both genetic, environmental 
factors contributing, and prevalence varies substantially among different 
ethnic groups (Gerstein & Haynes, 2001). Apart from racial factors, the 
prevalence of type II diabetes mellitus is associated with increasing age, 
increasing calorie intake and decreasing calorie expenditure and obesity, as 
well as pregnancy, certain drug therapy and undercurrent illness (Chew & 
Leslie, 2006; Marshall & Bangert,2008).  The increase in the prevalence of 
type II diabetes mellitus is closely linked to the upsurge in obesity. About 
90% of type II diabetes is attributable to excess weight. Furthermore, 
approximately 197 million people worldwide have impaired glucose 
tolerance, most commonly because of obesity and associated metabolic 
syndrome (Hossain, Kawar, & Nahas, 2007). This makes obesity being the 
burden in type II diabetes mellitus. 
 2
1.1 THE BURDEN OF OBESITY AND DIABETES 
 
1.1.1 Introduction 
 
The prevalence of overweight and obesity is increasing worldwide, 
especially in developing countries undergoing economic transition (Hjartker, 
Langseth, & Weidepass, 2008).Today more than 1.1 billion adults worldwide 
are overweight, and 312 million are obese ( Hossain et al., 2007). 
 
Obesity is defined as an excess of body fat with the body mass index (BMI) 
of >30kg/m2 (Seidell, 2000; Hjartaker et al., 2008). Obesity caused by 
excess food intake has increased worldwide and an estimated 64% 
Americans are now overweight or obese (Chew & Leslie, 2006). Overweight 
and obesity can lead to metabolic abnormalities, insulin resistance, type II 
diabetes, lipid disorders and cardiovascular disease (LeRoith, 2007).  
Obesity and type II diabetes are increasing in prevalence, bringing with them 
considerable morbidity and mortality. Type II diabetes and obesity are each 
characterized by the strong interaction of genetics and environment over 
time (Romao & Roth, 2008). 
 
 
1.1.2 Tools for identification of obesity 
 
Body mass index (BMI) and waist circumference are measures of obesity 
that can be useful in identifying individuals with these risk factors (Foucan, 
Hanley, Deloumeaux, & Suissa, 2002). 
 
1.1.2.1 Body Mass Index (BMI) 
Overweight and obesity are often determined by calculating the body mass 
index. It is defined as a weight in kilograms divided by the height in meters 
squared (kg/m2) (Foucan et al., 2002). Obesity is classified into classes 
based on body mass index (BMI). Figure 1.1.2.1 shows the different classes 
of obesity (Depre’s, Lemieux, & Prud’homme, 2001). 
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Table 1.1.2.1 Different classes of obesity 
Classification BMI 
Underweight <18.5 
Normal weight 18.5-24.9 
Overweight: >25.0 
Pre- obese 25.0- 29.9 
Obese Class I 30.0 – 34.9 
Obese Class II 35.0 - 39.9 
Obese Class III >40.0 
 
 
The correlation between the BMI number and body fatness is fairly strong: 
however the correlation varies according to sex, race, and age. These 
variations include the following examples:  
  At the same BMI, woman tend to have more body fat than man 
 At the same BMI, older people, on average, tend to have more body 
fat than young adults. 
 Highly trained athletes may have a high BMI because of increased 
muscularity rather increases body fatness (Prentice & Jebb, 2001). 
 
 
1.1.2.2 Waist circumference 
Waist circumference has been recognized as a good measure of abdominal 
fat, and particularly, the more metabolically active intra-abdominal fat and it 
is measured in centimetres (Foucan, et al., 2002).  
Obese male >102cm 
Obese female >88cm (Chew & Leslie, 2006) 
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1.1.3 Aetiology of Obesity 
 
It is generally accepted that obesity develops on the background of genetic 
predisposition and increased susceptibility may be developed by interaction 
with other factors, for example fetal programming. Weight gain and obesity 
develops in susceptible individuals due to a lifestyle characterised by 
physical inactivity and abundant availability of energy dense, high fat, 
palatable foods (Astrup, 2001). 
 
1.1.3.1 Genetic factors 
 
Several studies have shown that there is a strong genetic basis to the 
development of obesity. Obesity appears to be a polygenic disorder, with 
many genes currently linked or associated with a predisposition to excess 
adiposity (Chagnon, Rankinen, Snynder, Weisnagel, Perusse, & Bouchard, 
2002). 
 
1.1.3.2 Environmental factors 
Sedentary behaviour 
Physical inactivity is a major element in the development of obesity in 
westernized societies in children and adults alike. International studies have 
shown that television viewing is associated with an increase incidence of 
new cases of obesity, as well as a decrease in success rates for obesity 
intervention (Robinson, 2001). Television viewing exposes children to food 
marketing, increases opportunity of snacking on high energy foods and 
drinks, decreases opportunity of physical exercise, and reinforces sedentary 
behaviour (Batch & Baur, 2005). 
 
1.1.3.3 Dietary intake 
The abundant food energy supply in the majority of populations has removed 
limited energy availability as a restricting factor for the development of 
obesity. The proliferation of cheap, highly palatable, high fat, instant fast and 
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prepacked foods is assumed to contribute to over consumption and to divest 
consumers of control over preparation of their own foods (Astrup, 2001). 
 
1.1.3.4 Other risk factors for obesity in childhood and adolescence include: 
 Early infant feeding: Breastfeeding is possibly protective for the 
development of obesity (Butte, 2001). 
 Parental obesity, eating patterns, and attitudes: Parental obesity more 
than doubles the risk of adult obesity among both obese and 
 non- obese (Whitaker, Wright, Pepe, Seidel, & Dietz, 1997). 
 Early adiposity rebound: it is associated with increased body fatness 
in adolescents 
 Socioeconomic status: In some developed countries, poorer children 
or those in rural settings are more at risk of obesity 
 Ethnicity 
 Underlying medical disorders 
 Prescription drugs: Some drugs may contribute to obesity; these 
include glucocorticoids, antipychotic drugs, and some antiepileptic 
medications (Batch & Baur, 2005). 
 
1.1.4 Management and treatment of obesity 
 
Treatment must begin with long-term lifestyle changes, including increase 
physical activity and dietary modification. For overweight and obese 
individuals for whom lifestyle changes alone are insufficient, 
pharmacotherapy may be added (Cannon & Kumar, 2009; Joshi & Joshi, 
2009). 
 
1.1.4.1 Diet Therapy 
 
Many diet programs are available, but long term reduction of calorie intake 
and slow progressive weight loss is the most rewarding goal (Chew & Leslie, 
2006).The main aim is to provide a flexible program to help the individual to 
make sustainable changes in food choices and eating habits.  Dietary 
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interventions should emphasize energy reduction, lower fat food choices 
(low glycaemic index), increased vegetable and fruit intake, healthier snacks 
and decreased portion sizes. Water should be used as a main beverage, 
and drinks with high sugar content, including soft drinks and fruit drinks 
should limited (Batch & Baur, 2005). 
 
 
 
1.1.4.2 Physical activity 
 
Enhanced physical activity is an imported component of weight management 
programs. Physical activity is a term used to describe all movement 
produced by skeletal muscles which increases energy expenditure, whether 
exercise or sport (Astrup, 2001). 
 
1.1.4.3 Drug therapy 
 
Although somewhat effective, drug therapy, like other non-surgical 
modalities, achieves only a modest (~10%) weight reduction and required 
continued use to maintain this result. Most antiobesity drugs can be 
classified into 2 major groups by their mechanism of action: appetite 
suppression and/ or stimulation of thermogenesis and intestinal fat 
absorption. Currently the indications for the use of pharmacotherapy for 
obesity are BMI of 30 or a BMI of 27 with obesity related comorbidities. 
However, no data show that drug treatment of otherwise healthy obese 
subjects prevents future complication or improve long term outcome. Most 
patients regain weight once any drug therapy is discontinued, and the 
success of pharmacotherapy demands life style changes in diet, exercise 
and behaviour to increase effectiveness (Mun, Blackburn, & Matthews, 
2001).  
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1.1.4.4 Bariatric surgery 
 
About 5% of the US population is morbidly obese. This disease remains 
largely refractory to diet and drug therapy, but generally responds well to 
bariatric surgery. Effective weight loss was achieved in morbidly obese 
patients after undergoing bariatric surgery. A substantial majority of patients 
with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea 
experienced complete resolution or improvement (Buchwald, Avidor, 
Braunwald, Jensen, Pories, Fahrbach, & Schoeller, 2004). 
 
 
1.1.5 Motivation 
 
Obesity increases the risk of morbidities such as type II diabetes, 
cardiovascular disease, and certain cancers and reduces life expectancy. 
This makes obesity the most expensive disorder and course economic 
burden. 
 
Diabetes is a serious condition that affects all the body’s systems including 
kidneys, heart, eyes and limbs. This alone makes type II diabetes a life 
threatening disease; an expensive disease and economic burden that many 
individuals struggle to cope with. 
 
The rapid growth type II diabetes in South Africa is associated with the 
change of life style, and environmental factors brought by westernized way 
of life living in rural areas. Although westernized plays a big role, there are 
also genetic factors involved. Despite the technical advances in diagnosis 
and therapy of diabetes many people still use alternative forms of therapy 
due to the cost, traditional reasons and religion. Some of the people use the 
conventional medication together with the alternative therapy without 
informing their doctor. 
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A single medication can be effective for healing a particular disease; it can 
be more effective, when combined with an alternative therapy. In other 
cases when combined it can be less effective or even not effective at all. 
 
Most South Africans are taking conventional treatment together with the 
alternative treatment without knowing the synergistic and antagonistic 
effects. 
 
 
1.2 Insulin 
1.2.1 Mechanism of action 
 The basic metabolic defect in diabetes mellitus is that glucose cannot enter 
the cells, either because there is insulin deficiency or insulin resistance. This 
defect can be managed by administration of exogenous insulin. It decreases 
blood glucose concentration by promoting glucose uptake from blood into 
cells where it has major effects on carbohydrate, lipid and protein 
metabolism. The key target tissues for insulin action are liver, skeletal 
muscle, and adipose tissue, although insulin influences the function of most 
tissues. At a cellular level, insulin stimulates glycogen synthesis, lipid 
synthesis and glucose oxidation and simultaneously inhibits glycogenolysis, 
lipolysis and gluconeogenesis (Patel, 2003; Bishop et al., 2010). 
 
1.2.2 Insulin molecule 
The insulin molecule contains two polypeptide chains, Chain A (21 Amino 
acids) and chain B (30 amino acids), linked by two disulphide bridges. Chain 
A has an additional disulphide bridge. The active site of hormone is located 
on the carboxy-terminal region of chain B. The crystalline state of insulin 
allows insulin to be stored in the most concentrated form and protects the 
molecule from further proteolytic cleavage (Patel, 2003). 
 
1.2.3 Insulin secretion 
Endogenous insulin secretion is affected by a wide range of physiological 
agents. The secretory response of the beta – cell to physiological stimuli 
occurs within seconds, requires the presents of calcium, and is controlled by 
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fluctuations in extra concentrations of nutrients and hormones. The 
autonomic nervous system also directly contributes to the control of insulin 
secretion. The secretory response of the beta-cell may be directly activated 
by primary stimuli, modified by secondary stimuli or inhibited by various 
agents (Patel, 2003). 
 
 
1.2.3.1 Primary stimuli 
It directly affects insulin secretion via a mechanism involving calcium signal. 
The insulin secretory mechanism is triggered when the calcium 
concentration reaches threshold level and the examples of the stimuli 
include glucose, amino acids and fatty acids (Patel, 2003). 
 
 
1.2.3.2 Secondary stimuli 
Secondary stimuli modulate the beta cell secretory response to primary 
stimuli, but do not directly affect insulin secretion. The mode of action for 
these agents involves a cyclic AMP signal. It may increase the response of 
beta cell to primary stimuli by promoting release of calcium from the storage 
pools and thus increasing the availability of calcium in cytoplasmic 
compartment. The examples of secondary stimuli are glucagon, 
prostaglandins E1 and E2 and sulphonylureas (Patel, 2003). 
 
1.2.3.3 Inhibitory agents 
Inhibitory agents reduce the response of the beta cell secretory mechanism 
to both primary and secondary stimuli. The adrenergic nervous system can 
inhibit insulin secretion either by releasing adrenergic neurotransmitter 
noradrenaline from the nerve terminals in the beta cell islets or by releasing 
the hormone adrenaline from the adrenal medulla. The example of inhibiting 
agent is diazoxide (Patel, 2003). 
 
1.2.4 Insulin receptor 
The action of insulin is mediated via insulin receptors which are located both 
on the cell surface of the target tissues and also on intracellular membranes. 
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The receptor protein consists of four subunits: two extracellular alpha 
subunits which bind insulin on the cell surface; and two beta subunits which 
transverse the plasma membrane. The intracellular domain of the beta 
subunits contains tyrosine- specific protein kinase. It has been proposed that 
insulin binding to the alpha subunit causes conformation change which leads 
to autophosphorylation of the receptor and activation of tyrosine kinase 
which in turn initiates the phosphorylation cascade (Patel, 2003; Tusie- 
Luna, 2005). Insulin receptor complexes diffuse literally towards each other 
within the plain of plasma membrane and form aggregates. Aggregate rich 
areas of the membrane become internalized by the process of endocytosis. 
The insulin that dissociates from the receptor may be recycled back to the 
cell surface. The availability of insulin receptors on the cell surface is 
controlled by the concentration of extracellular insulin. The process of 
regulating the number of receptors on the cell surface by receptor- mediated 
endocytosis may be physiologically important for preventing overstimulation 
of target cells by insulin (Patel, 2003). 
 
 
1.2.5 Glucose uptake 
Glucose is transported by specific carriers which carry glucose across the 
cell membrane faster than would occur by diffusion alone. A family of six 
transporters (GLUT1 to GLUT6), expressed in the different tissues, have 
been identified. Glucose uptake by muscle (80% of the total body glucose 
uptake) is mediated by circulating glucose concentrations. The primary form 
of transporter in the skeletal muscle and adipose tissue is GLUT4. Glucose 
uptake by the liver, brain, nervous tissue, renal medulla and erythrocytes is 
independent of glucose concentration (Patel, 2003). 
 
 
1.2.6 Insulin degradation 
 
Insulin degradation is a regulated process that plays a role in controlling 
insulin action by removing and inactivating the hormone. Abnormalities in 
insulin clearance and degradation are present in various pathological 
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conditions including type II diabetes and obesity and may be important in 
producing clinical problems. The uptake, processing, and degradation of 
insulin by cells is a complex process with multiple intracellular pathways. Most 
evidence supports IDE as the primary degradative mechanism, but other 
systems (PDI, lysosomes, and other enzymes) undoubtedly contribute to 
insulin metabolism. Recent studies support a multifunctional role for IDE, as 
an intracellular binding, regulatory, and degradative protein. IDE increases 
proteasome and steroid hormone receptor activity, and this activation is 
reversed by insulin. This raises the possibility of a direct intracellular 
interaction of insulin with IDE that could modulate protein and fat metabolism. 
The recent findings would place intracellular insulin-IDE interaction into the 
insulin signal transduction pathway for mediating the intermediate effects of 
insulin on fat and protein turnover (Duckworth, Bennet, & Hammel, 1998). 
 
1.3 DIABETES MELLITUS: CLASSIFICATION, DIAGNOSIS, 
PREVENTION AND TREATMENT 
 
1.3.1 Introduction 
Diabetes mellitus is a systematic metabolic disorder characterized by a 
tendency to chronic hyperglycaemia with disturbances in carbohydrate, fat 
and protein metabolism that arise from a defect in insulin or action or both. It 
is a common condition with a prevalence of approximately 4% in the western 
world (Marshall & Bangert, 2008). The development of type II diabetes is 
characterized by the malfunction of pancreatic beta-cells in combination with 
insulin resistance, beta- cells tend to increase their production of insulin (Sia, 
2004). However in situations where insufficient insulin is produced, the onset 
of glucose intolerance exists (Porte, 1991).Signs and symptoms include 
polydipsia, polyphagia, polyuria, rapid weight loss, hyperventilation, mental 
confusion and possible loss of consciousness (Bishop et al., 2010). 
 
The social and economic burden imposed by this disease, is highlighted by 
the observations that type II diabetes is a major cause of end renal disease, 
blindness, limb amputation, and cardiovascular disease (Gottlieb, 2000).It is 
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classified into 4 categories, type I, type II gestational diabetes and other 
specific types of diabetes (Bishop et  al., (2010). 
 
 
Type I 
It is characterised by inappropriate hyperglycemia primarily a result of 
pancreatic islet beta cell destruction and tendency of ketoacidosis. It is a 
result of cellular mediated autoimmune destruction of beta cells of the 
pancreas, causing an absolute deficiency of insulin. It constitutes only 10% 
to 20% of all cases of diabetes and commonly occurs in children and 
adolescence. It is usually initiated by environmental factor or infection in 
individuals with genetic predisposition (Bishop et al., 2010). 
 
Type II  
It is characterised by hyperglycaemia as a result of an individual resistance 
to insulin with an insulin secretory defect. It results in a relative, not an 
absolute, insulin deficiency. Type II diabetes constitutes the majority of the 
diabetes cases. Most patients with this type are obese or having an 
increased percentage of body fat distribution in the abdominal region. This 
type goes undiagnosed for years and is associated with a strong 
predisposition, with patients at increased risk in an increase of age, obesity 
and lack of physical exercise. It has milder symptoms than type I, with 
seldom ketoacidosis occurring. The patients are more likely to go into 
hyperosmolar coma and are at increased risk of developing macrovascular 
and microvascular complications (Bishop et al., 2010). 
 
Other 
 
Other specific types of diabetes are associated with certain conditions 
(secondary), including genetic defects of beta cell function or insulin action, 
pancreatic disease, diseases of endocrine origin, drug or chemical induced, 
insulin receptor abnormalities, and certain genetic syndromes (Bishop et al., 
2010). 
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Gestational Diabetes mellitus 
It is any degree of glucose intolerance with onset or first recognition during 
pregnancy (Bishop et al., 2010).Table 1.3.1 outlines the classification of 
diabetes mellitus. 
 
Table 1.3.1 Classification of diabetes mellitus 
Diabetes Mellitus Classification Pathogenesis 
Type 1 Beta cell destruction 
Absolute insulin deficiency 
Autoantibodies 
 Islet cell autoantibodies 
 Insulin antibodies 
 Glutamic acid decarboxylase 
autoantibodies 
 Tyrosine phosphatase IA-2 
and IA-2B autoantibodies 
Type 2 Insulin resistance with insulin 
secretory defect 
Relative insulin deficiency 
Other Associated with secondary 
conditions 
 Genetic defects of beta cell 
function 
 Pancreatic disease 
 Endocrine disease 
 Drug or chemical induced 
 Insulin receptor abnormalities 
 Other genetic syndrome 
  
Gestational Glucose intolerance during 
pregnancy 
Due to metabolic and hormonal 
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changes 
 
(taken from Bishop et  al., 2010). 
 
 
1.3.2 Criteria for the Diagnoses of Diabetes Mellitus 
 
According to ADA recommendations, all adults older than 45 years should 
have measurement of fasting blood glucose every 3 years unless the 
individual is otherwise diagnosed with diabetes. Testing should be carried 
out at an earlier age or more frequently in individuals who display overweight 
tendencies (BMI >25 kg/m2) and has additional risk factors, as follows: 
 Habitually physically inactive 
 Family history of diabetes first-degree relative 
 Membership of high risk minority population 
 History of gestational diabetes mellitus or delivering a baby weighing 
more than 4.1 kg  
 Hypertension (blood pressure >140/90mmHg) 
 Low high density lipoprotein (HDL) cholesterol 35mg/dl) (0.90mmol/L) 
 Elevated triglyceride >20mg/dl(2.82mmol/L) 
 A history of impaired glucose tolerance 
 Woman with polycystic syndrome 
 Other clinical conditions associated with insulin resistance 
 History of cardiovascular disease (Bishop et al., 2010). 
 
1.3.2.1 Diagnostic criteria for diabetes mellitus 
 
Three ways to diagnose diabetes are possible, and each, in the absence of 
unequal hyperglycaemia, must be confirmed, on a subsequent day, by any 
one of three methods given on the table. These methods are 1) symptoms of 
diabetes plus random plasma glucose of > 200mg/dl, 2) a fasting plasma 
glucose of 126mg/dl or 3)an oral glucose tolerance (75g glucose load) level 
>200mg/dl The preferred test for diagnosing diabetes is the measurement of 
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the fasting plasma glucose level. An intermediate group who did not meet 
the criteria of diabetes mellitus but who had glucose levels above normal. 
Fasting glucose levels >110mg/dl but < 126mg/dl were called the impaired 
fasting glucose group and patients who had 2 hour OGGT levels of 
>140mg/dl but <200mg/dl was defined as impaired glucose tolerance 
(Bishop et al., 2010). 
 
 
 
1.3.3 Prevention 
 
Type II diabetes can largely be prevented by changes in lifestyle of high risk 
subjects. A study was done where 522 middle aged overweight people were 
used and the study consists of: 
 172 men and 350 woman 
 mean age 55 years  
 mean BMI 31 kg/m2 
  With impaired glucose tolerance to either intervention group or 
control group.  
 
Each subject in the intervention group received individualized 
counselling aimed at reducing weight, total intake of fat, and intake of 
saturated fat and increase intake of fibre and physical activity. An oral 
glucose tolerance test was performed annually; the diagnosis of 
diabetes was confirmed on the second test. The mean duration of the 
follow-up was 3.2 years. The risk of diabetes was reduced by 58% in the 
intervention group 
 this risk reduction was directly linked to lifestyle changes 
 those who lost 5% of their body weight had a 74% risk reduction 
 those exceeded the recommended 4 hours exercise per week had a 
risk reduction (Tuomilehto, Lindstrom, Errikson, Valle, Hamalainen, 
Ilanne-Parrika,……. Uusitupa, 2001; Chew & Leslie, 2006). 
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1.3.4 Diabetic Treatment 
 
Type II diabetes is best treated by a change in lifestyle combined with 
medication. Lifestyle includes weight loss, exercise, dietary changes. 
Medications include sulphonylureas, thiazolidione, biguanide and insulin 
(Chadwick, 2003). 
 
 
1.3.4.1 Weight loss 
 
Studies were done by Indiana University School of Medicine, which revealed 
that weight reduction by approximately 10% or less, for obese patients with 
NIDDM, hypertension or hyperlipidemia, appeared to improve glycemic 
control, reduce blood pressure, and reduce cholesterol levels, respectively. 
Modest weight reduction also appeared to increase longevity in obese 
individuals. In conclusion, a large proportion of obese individuals with NIDDM, 
hypertension, and hyperlipidemia experienced positive health benefits with 
modest weight loss. For patients who are unable to attain and maintain 
substantial weight reduction, modest weight loss should be recommended; 
even a small amount of weight loss appears to benefit a substantial subset of 
obese patients (Goldstein, 1992). 
 
 
1.3.4.2 Exercise 
 
Exercise increases energy consumption, and under normal physiological 
conditions this increase in requirement for energy is met by an increase in 
utilization of glucose and free fatty acids. Blood glucose concentrations are 
maintained within the normal range through the action of counter-regulatory 
hormones such as glucagon and catecholamines. Exercise is a fundamental 
component of diabetes management and it is therefore important that 
diabetic patients exercise regularly. The benefits of exercise in diabetes in 
diabetes mellitus include: 
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 Improved glycaemic control due to increased insulin sensitivity and 
glucose tolerance 
  Reduction of cardiovascular risk factors due to an improvement in 
blood lipids profile, blood pressure and cardiovascular fitness and 
enhancement of body weight loss in obese diabetic patients.  
 
It is important that diabetic patients are assessed for the risks associated 
with exercise before embarking on any exercise programme (Patel, 2003). 
 
Risks include: 
 Immediate and prolonged hypoglycaemia due to enhanced uptake of 
glucose by tissue induced by exercised. 
 Exacerbation of hyperglycemia and possible development of ketosis.  
   Exacerbation of microvascular diabetic complications with some 
types of strenuous exercise (Patel, 2003).       
                                                                                                                                        
1.3.4.3 Diet 
 
The diet for diabetic patient is, in principle, no different from the diet 
considered healthy for the population as a whole, except that refined sugar 
should be avoided. Particular attention should be paid to calories and the 
carbohydrate and fat content of the diet.  Diets or food plans for diabetes 
include unrefined carbohydrates rather simple sugars such as sucrose. 
Carbohydrate is absorbed relatively slowly from fibre rich foods, but blood 
glucose may rise rapidly when refined sugar is eaten. For example, the 
glucose peak seen in the blood after eating an apple is much flatter than 
seen after drinking the same amount of carbohydrate as apple juice. Thus, 
foods with lower glycemic index are preferable (Chew & Leslie, 2006).  
 
1.3.4.4 Sulphonylureas 
 
Sulphonylureas increase insulin secretion from pancreatic beta cell by 
closing ATP-sensitive potassium channels, depolarizing the beta cell plasma 
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membrane and increasing intracellular calcium concentration (Chew & 
Leslie, 2006). It lowers both blood glucose and HbA1c levels on initial 
treatment of newly diagnosed type II diabetic patients. Failure to control 
hyperglycemia on initiating treatment with a sulphonylurea (primary failure) 
is usually due to inappropriate use of the sulphonylurea in type I diabetes. In 
some patients, the hypoglycemic effect of sulphonylurea tapers off with 
continued treatment, with HbA1c patients of values returning to pre-
treatment levels secondary failure). It has been proposed that chronic 
stimulation of islet beta cells, particularly by long-acting sulphonylureas, 
causes premature beta cell exhaustion and may also increase the output of 
immature beta cell products such as proinsulin and split proinsulin, which in 
turn may increase atherogenesis (Patel, 2003). Drug interactions and side-
effects, sulphonylureas bind to circulating albumin and may be displayed by 
other drugs that compete for their binding sites namely warfarin (Chew & 
Leslie, 2006). 
 
1.3.4.5 Biguanides 
 
Biguanides are guanide derivative in which two molecules of guanide are 
linked with elimination of amino group. In 1950’s three major biguanide 
became available for clinical use, phenformin, metformin and burformin. 
Phenformin was withdrawn for use because of lactic acidosis (Bailey, 1992; 
Chadwick, 2003) Metformin is the drug of preference in the presence of 
obesity and insulin resistance (Chew & Leslie, 2006). 
 
1.3.4.6 Thiazolidinediones 
 
The thiazolidinediones act on the peroxisome proliferator-activated 
receptors. These nuclear receptors regulate DNA expression including 
genes involved in lipid metabolism. They are effective in improving glycemic 
control in patients with insulin resistance and may be used as monotherapy 
or in combination with other antidiabetic agents. They improve insulin 
sensitivity and insulin secretion and they can also be used in conjunction 
with either metformin or a sulphonylurea. They can be used in mild renal 
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failure, in elderly and in patients with polycystic syndrome. They are contra 
indicated in pregnancy. Regular liver function tests are, advised when using 
this group of drugs because of Troglitazone that had hepatotoxicity and now 
it has been withdrawn. They can cause weight gain and fluid retention, even 
precipitate cardiac failure, particularly in patients on insulin (Bailey, 2005; 
Chew & Leslie, 2006). 
  
1.3.4.7 Insulin administration 
 
The aim of insulin therapy is to mimic insulin action in patients who have a 
relative or absolute insulin deficiency. It is indicated in type I, type II diabetes 
mellitus when other forms of therapy have failed, during (illness and in acute 
myocardial infarction) and pregnancy when therapy other than diet alone is 
required. It is destroyed in the gastrointestinal tract and so must be given 
parentally: usually subcutaneous but intravenously or intramuscularly in 
certain circumstances. One of the problems is avoid wide fluctuations 
plasma insulin, and, thus, blood glucose. It can be injected in several areas; 
absorption is the fastest in the abdomen and slower on the thigh. 
 
Insulin is administered in different regimen and dosed which are 
individualized. Different regimens for insulin treatment include once daily 
injection with bedtime intermediate insulin for patients on diabetes tablets, 
two times daily injections of fast acting and intermediate acting (or premixed) 
insulin, three times daily injections including twice daily regimen plus midday 
fast acting insulin and four times daily injections including three times daily 
meal fast-acting insulin and slower insulin at bedtime. The insulin 
concentration in blood occurs within 30 - 60min and peaks at 2 - 3hours in 
soluble mealtime insulin, 20 - 30min and peaks at 1 - 2hours in rapid acting 
analogue and 30 - 90min and peaks at 4 - 6hours in intermediate-acting 
insulin .This type of treatment has complications that include circulation of 
insulin antibodies can affect insulin action, hypoglycaemia, weight gain, 
lipohypertrophy, lipotrophy and insulin oedema (Chew & Leslie, 2006). 
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1.3.4.8 Alternative medication 
 
Despite the impressive technical advances made in the diagnosis and therapy 
of diabetes many individuals still use alternative forms of therapy due to cost, 
religious or traditional reasons (Chadwick, 2003). According to Maduna 
(2006), “About 80% of people in Southern Africa use traditional medicine, 
often in conjunction conventional medications, raising a possibility of 
synergistic or antagonistic drug interaction”. Many plants are used by 
traditional healers around South Africa as a substitute for western medication 
(Chadwick, 2003). Some people even use them simultaneously. According to 
Gottlieb (2000), you should use alternative remedies only as part of treatment 
program that is guided and monitored by a qualified doctor in partnership with 
a qualified alternative practitioner, both who have experience in caring for the 
condition. Medicinal plants used to treat hypoglycaemic or hyperglycaemic 
conditions are of considerable interest for ethno-botanical community as they 
are recognized to contain valuable medicinal properties in different parts of 
the plant and a number of plants have shown varying degrees of 
hypoglycaemic and anti-hyperglycaemic activities (Grover, Yadav, & Vats, 
2002). 
 
Plants such as garlic, aloe vera, burdock root, karela (bitter melon),  
Jerusalem artichoke and fenugreek seeds have all been studied and showed 
some benefit in lowering plasma glucose levels, but overall, there is little 
information about herbal remedies (Patel, 2003; Gholamali, Maleki, 
Motadayen, & Sirus, 2005). 
 
1.4 Review of the medications to be used throughout the project 
 
Two anti-diabetic drugs were used throughout the project, the biagunide 
metformin and the medicinal plant Sutherlandia frutescens.  The mode of 
action and side effects of these drugs were studied because of their vital 
importance. 
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1.4.1 Metformin 
 
Metformin, a biguanide, is the drug of preference in the presence of obesity 
and insulin resistance (Atabek & Pirgon, 2008; Desilets, Dhakal-Karki, & 
Dunican, 2008). It reduces vascular risks in patients with diabetes mellitus. It 
is associated with weight loss. The mechanism of action is unclear, but it 
decreases gluconeogenesis, and hence, hepatic glucose output, and reduces 
fasting blood glucose. It also increase insulin stimulated glucose uptake in 
skeletal muscles (Bailey, 2005; Chew & Leslie, 2006). Metformin is a well-
established drug of diabetes management, both monotherapy in early stages 
of type II diabetes and as adjunct therapy to virtually every other anti- 
hyperglycemic medicine available today. Despite low potency and long list 
contra indications, metformin has remained successful and even expanded 
experimental use due to its well established effects on glucose metabolism 
and, as more recently demonstrated, its benefits on other cardiovascular 
factors (Strack, 2008). 
 
A study was done that show that metformin activate the AMP-activated 
protein kinase (AMPK) in intact cells and in vivo. In intact cells, metformin 
stimulated phosphorylation of the key regulatory site (Thr-172) on the catalytic 
(α) subunit of AMPK. It did not affect phosphorylation of this site by either of 
two upstream kinases in cell-free assays, although an increase in upstream 
kinase activity in extracts of metformin-treated cells was detected. Metformin 
has been reported to be an inhibitor of complex 1 of the respiratory chain 
(Hawley, Gadalla, Olsen, & Hardie, 2002). 
 
The mechanism of action involves an increase in the movement of insulin-
sensitive glucose transporter molecules to the cell membrane; an increase in 
activity of enzyme glycogen synthase promotes synthesis of glycogen (Krentz 
& Bailey, 2005). It also acts in an insulin dependent manner to suppress 
oxidation of fatty acids and reduce triglyceride levels in patients with 
hypertriglyceridemia (Bailey, 1993). This reduces the energy supply for 
hepatic gluconeogenesis and has favourable effects on glucose fatty acid 
cycle (Chew & Leslie, 2006). 
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The pharmacokinetics of metformin indicates that it is quickly absorbed and 
eliminated unchanged in the urine. There is little binding of metformin to 
plasma proteins and is not metabolised, so does not interfere with metabolism 
of co -administered drugs. It is widely distributed, high concentration being 
retained in the walls of gastrointestinal tract, this provides a reservoir from 
which plasma concentration are maintained. Nevertheless, peak plasma 
metformin concentrations are short lived in patients with normal renal function. 
The metformin plasma half-life is 2 - 5 hours, and almost 90% of an absorbed 
dosage is eliminated within 12hours (Bailey & Turner, 1996). 
 
Metformin is efficient because it is unlikely to cause severe hypoglycaemia 
and does not stimulate insulin secretion; bodyweight tends to stabilize or 
decrease slightly. Small improvements in the blood lipid profile may be 
observed in hypelipidaemic patients: plasma triglyceride, fatty acids and low 
density proteins end to decrease and HDL tend to rise (Krentz & Bailey, 
2005). 
 
Metformin has many side effects, abdominal discomfort and other 
gastrointestinal adverse effects, including diarrhoea, are encountered fairly  
common during the introduction of metformin. Metformin is contra indicated in 
patients with renal or hepatic disease or where there is an increased risk of 
lactic acidosis (Chew & Leslie, 2006). 
 
1.4.2 Sutherlandia frutescens 
 
Sutherlandia frutescens is one of six currently recognized sutherlandia 
species, all which are confined to South Africa. These six species can be 
reduced to two namely Sutherlandia frutescens and Sutherlandia tomentosa, 
then further subdivided into three subspecies namely frutescens, microphylla 
and speciosa. The species are distinguished from one another by their 
habitat, the shape of the pods and pubescence of the leaflets (Van Wyk, Van 
Oudshoorn, & Gericke, 1997; Moshe, 1998). 
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The genus has been renamed to Lessertia but is still referred to by its more 
favoured name of Sutherlandia (Müller, 2002). Sutherlandia have both 
medicinal and horticultural uses. Leaf infusions of Sutherlandia frutescens are 
used to treat stomach problems even internal cancers, colds, influenza, 
chicken pox, diabetes, relieve eye problems, piles, inflammation, liver 
problems (Moshe, Van der Bank, Van der Bank, & Van Wyk, 1998; Ojewole, 
2004).The recommended dosage is 300 mg twice daily or 600mg per day 
(Van Wyk & Albrecht ,2008).  
 
The presence of high levels of free amino acids, non- protein amino acids 
such as canavanine and GABA, the cyclitol pinitol, flavonols and triterpenes 
provide the plausible hypotheses on how these compounds, individual or 
collectively, may be responsible for the reputed efficacy in wide range 
ailments. Results of animal studies, as well as a phase I clinical study, have 
shown no indications of toxicity (Van Wyk & Albrecht, 2008).  
 
 
 
1.4.2.1 L-Canavanine 
 
It is known to occur in high levels in certain seeds. This potent non-protein 
amino acid is an L-arginine antagonist with documented antiviral, anti-
bacterial, anti-fungal and anticancer activities. An average of 2.2mg of L-
canavanine per dry gram of leaf material of sutherlandia was found. L-
canavanine is a potent L-arginine antagonist that has patented anticancer 
(Crooks & Rosenthal, 1994). It is also a selective inhibitor of inducible nitric 
oxide synthase and therefore has possible application in the treatment of 
septic shock and chronic inflammation (Anfossi, Massucco, Cavalot, Giori, 
Tassone, & Trovati, 1999; Sia, 2004). 
 
1.4.2.2 Pinitol 
 
Pinitol, a known anti-diabetic agent that may have an application in treating 
wasting in cancer and AIDS  (Ostlund & Sherman, 1996). It exerts insulin like 
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effect, resulting in lower blood sugar levels and increases availability of 
glucose for cell metabolism (Bates, Jones, & Bailey, 2000). According to 
Moshe (1998) 14 mg/g of dry leaves is effect for mammals. 
  
1.4.2.3 GABA 
 
GABA is present in Sutherlandia in levels up to 0.4 mg/g dry weight. This 
neurotransmitter participates outside the CNS in diverse functions. Recently it 
was demonstrated that GABA inhibits the migration of tumor cells in vitro and 
this activity may be important in preventing metastasis of various cancers in 
vivo (Ortega, 2003). GABA if present in patient’s circulation at sufficiently high 
levels may potentially contributes to the improvement in mood and wellbeing 
experienced by many patients, and indirectly contributes to the improved 
wasting in HIV/AIDS patients (Tai, Cheung, Chan, & Hasman, 2004). 
 
1.4.2.4 Novel Triterpenoid Glucoside 
 
It is known as SU1 and has been isolated and characterized, and is one of the 
key compounds used in the selection of raw material propagation. This 
compound has promising biological activities, and is still the subject of 
ongoing research (Van Wyk & Albrecht, 2008). 
 
1.4.2.5 Flavonoids 
Sutherlandia leaves are known to contain at least six flavonoids (Moshe, 
1998). 
 
 
1.5 Tissues that were examined in this study: Pancreas, Liver and 
Kidney  
 
1.5.1 Introduction 
 
There are three tissues that have examined in this study, they have a specific 
biochemical function in the glucose metabolism and they are affected by 
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diabetes mellitus. Histopathology and biochemical testing is used in this study 
to test the effectiveness of the medication in these tissues, whether there is 
improvement in glucose metabolism or not. 
 
1.5.2 Pancreas 
 
The pancreas contains endocrine cell clusters called pancreatic islets (islets 
of Langerhans). The islets secrete at least five hormones and pancreatic 
products, the most important of which are insulin, glucagon, and somastatin. 
 
 
1.5.2.1 Insulin 
 
It is secreted by the beta cells of the islets of Langerhans when these cells 
detect an increase in body glucose. The release of insulin causes an 
increased movement of glucose into the cells and increase glucose 
metabolism. It decreases plasma glucose levels by increasing the transport 
entry of glucose in the muscle and adipose tissue by way of nonspecific 
receptors. It also regulates glucose by increasing glycogenesis, lipogenesis, 
and glycolysis and inhibiting glycogenolysis however, promote the liver’s 
synthesis of glycogen from the absorbed glucose (Voet & Voet, 2004; Bishop 
et al., 2010). 
 
1.5.2.2 Glucagon 
 
It is secreted by alpha cells when blood glucose concentration falls between 
meals. In the liver it stimulates gluconeogenesis, glycogenolysis, and the 
release of glucose into the circulation. In adipose tissue it stimulates the fat 
catabolism and the release of free fatty acids. Glucagon is also released in 
response to rising amino acid levels in the blood after a high-protein diet meal. 
By promoting amino acid absorption, it provides cells with raw material for 
gluconeogenesis (Saladin, 2004). 
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1.5.2.3 Somastatin 
 
It is secreted in the delta cells when blood glucose and amino acids rise after 
a meal. It inhibits various digestive functions, but also acts locally in the 
pancreas as a paracrine secretion. It also inhibits the secretion of glucagon 
and insulin by the neighbouring alpha and beta cells (Saladin, 2004). 
 
 
1.5.3 Liver 
 
The liver is the largest internal organ of the human body. It is functionally 
complex organ that plays a critical biochemical role in the metabolism, 
digestion, detoxification, and elimination of substances from the body. 
 
1.5.3.1 Carbohydrate metabolism 
 
During fasting, the liver plays an important role in maintaining blood glucose 
levels by glycogenolysis (breaking of stored glycogen) or gluconeogenesis 
(generation of glucose from amino acids and fatty acids). This protective 
mechanism may be impaired in severe liver dysfunction, such as fulminant 
acute liver necrosis, thereby resulting in hypoglycaemia. Patients may require 
regular monitoring of blood glucose levels (Hughes & Jefferson, 2008). 
 
 1.5.3.2 Lipid metabolism 
 
 It degrades chylemicron remnants 
 It carries out most of the body’s lipogenesis and synthesis cholesterol 
and  phospholipids 
 It produces VLDLs to transport lipids to adipose tissue and other 
tissues for storage or use and stores fat in its own cells 
 It carries out most of the beta oxidation of fatty acids 
 It produces ketone bodies from excess acetyl CoA 
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 It produces HDL shells, which pick up excess cholesterol from the 
other tissues and return it to the liver 
 Excretes the excess cholesterol in bile (Saladin, 2004). 
 
Multiple dysfunctions such as β oxidation, very low density lipoprotein 
secretion, and pathways involved in the synthesis of fatty acids may 
complicate leading to accumulation of lipid droplets into hepatocytes and 
cause hepatic stenosis (Nguyen, Leray, Diez, Serisier, & Le Bloc’h, 2008). 
 
1.5.3.3 Protein and Amino acid Metabolism 
 
 It carries out deamination and transamination of amino acids 
 It removes NH2 from glutamic acid and converts the resulting 
ammonia to urea by means of the orthinine cycle (Saladin, 2004). 
 
1.5.4 Kidney 
 
It has been demonstrated that the kidney is responsible for ~10-25% of 
systemic glucose turnover in postabsorptive humans. Renal glucose 
production is suppressed and glucose utilization is stimulated during 
physiological hyperinsulinemia, which results in net renal glucose uptake. 
Concomitant and proportional reductions in circulating free fatty acid and in 
systemic and renal gluconeogenesis from glycerol suggest that insulin exerts 
its peripheral effects on systemic glucose production and utilization, in part, by 
reducing renal glucose production and enhancing renal glucose utilization via 
inhibition of adipose tissue lipolysis. It was concluded that glucose production 
and utilization by the kidney are important insulin-responsive components of 
glucose metabolism in humans (Cersosimo, Garlick, & Ferretti, 1999). 
Oxidative stress has been suggested to play a crucial role in the pathogenesis 
of diabetic complications including nephropathy (Zhang, Khanna, Chan, 
Campbell, & Ansari, 1997).  
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CHAPTER 2 
                    Introduction to the present study 
Diabetes mellitus is a serious condition that affects all the body’s systems 
including kidneys, heart, eyes and limbs. This alone makes Type II diabetes a 
life threatening disease, an expensive disease and an economic burden that 
many individuals struggle to cope with. 
 
  The rapid growth of type II diabetes in South Africa is associated with the 
change of life style, and environmental factors brought by the westernized 
way of living in rural areas. Although westernization plays a big role, there is 
an also genetic factor involved. Despite the technical advances in diagnosis 
and therapy of diabetes many people still use alternative forms of therapy due 
to the cost, traditional reasons and religion. Some of the people use the 
conventional medication together with the alternative therapy without 
informing their doctor (Egede, Ye, Zheng, & Silverstein, 2002; Chadwick, 
2003). 
 
A single medication can be effective for healing a particular disease; it can 
also be more effective, when combined with another alternative therapy. In 
other cases when combined it can be less effective or even not effective at all. 
 
Most South Africans are taking conventional treatment together with the 
alternative treatment without knowing the synergistic and antagonistic effects.  
 
In this study synergistic and antagonistic effect of indigenous plant 
Sutherlandia frutescens which is hypoglycaemic agent and conventional 
treatment for diabetes mellitus metformin are tested on Wistar rats. Knowing 
the effects of these medications when used as a combination will be able to 
improve management in treatment of diabetes mellitus type II. 
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         CHAPTER 3 
              RESEARCH DESIGN AND METHODOLOGY 
 
3.1 Introduction 
 
This study was aiming to investigate pathological changes in male Wistar rats 
after co-treatment of type II diabetes with metformin and Sutherlandia 
frutescens and possible synergistic or antagonistic effects. An animal model 
was used to investigate metabolic effects of the disease and the effects of the 
medications in plasma and tissues. Wistar rats are used in the study because 
they are relatively inexpensive, in terms of housing and feeding, and are easy 
to handle, it was for this reason that they were chosen as the model of 
preference (Chadwick, 2003). 
 
 
3.2 Research Approach 
 
This study was approved by the animal ethical committee of Nelson Mandela 
Metropolitan University. The study group consisted of thirty five selected male 
Wistar rats, with an average weight of 260g .The rats were obtained from the 
animal unit of Medical Research Council. The rats were randomly divided into 
10 cages, with 3 to 4 rats per cage for purpose of feeding and administering of 
drugs. They were housed in an animal room with constant temperature of 
23oC and a day/night cycle of 12 hours. 
 
The thirty five rats were divided into five groups, seven in each group.  There 
were two control groups and three test groups. Only the first control group 
was on a low fat diet (normal rat pellets) and second control group and test 
groups were on a high fat diet which induces obesity, insulin resistance and 
leads a typical prediabetic state for 12 weeks (Buettner, Parhofer, 
Woenckhaus, Wrede, Kunz-Schughart, Schoelmerick, & Bolheimer, 2006). 
After 11.5 weeks medication was administered by oral gavaging to the test 
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groups for 4 weeks and control groups received water.  Table 3.2.1 and Table 
3.2.2 illustrate how the rats were divided. 
 
 
 
Table 3.2.1 Division of rats according to their diet and treatment (Test group) 
Groups Diet Treatment Number of rats 
Group 3  
(Plant) 
High fat Sutherlandia 
frutescens 
7 
Group 4 
(Metformin) 
High fat Metformin 7 
Group 5  
(Plant + Met) 
High fat Metformin+ 
Sutherlandia 
frutescens 
7 
 
Group 1 and group 2 received no treatment; they received only food and 
water. 
 
Table 3.2.2 Division of Control groups according to their diet 
Groups Diet Number of rats 
Group 1 
LFD  
Low fat 7 
Group 2 
HFD 
High fat 7 
 
Although the study started with 7 rats on each group, some died before 
sacrifice and no blood could be obtained from these rats for analysis. At the 
end of the experiment LFD, Metformin and plant +metformin groups had 6 
rats. 
 
The cages were cleaned three times a week and the rats were weighed every 
week. They were given food and water on a daily basis and the test groups 
 31
received the various treatments by oral gavaging on a daily basis and control 
rats received water. During the first week, prior to drug administration, the rats 
were gavaged with water to familiarise them with the technique of gavaging. A 
plastic gavaging needle was inserted into the rear of the mouth of the rat to 
induce swallowing of the needle which was held upright and pushed it to the 
lower oesophagus and stomach. Correct animal handing skills were required, 
to ensure accurate dosing of the medication (Van Gend, 2008).  
 
 
3.2.1 Preparation of medication 
3.2.1.1 Sutherlandia frutescens 
The medicinal freeze-dried plant was weighed and an amount of 0.200 g was 
dissolved in 5 ml of deionized water. The plant was given as 0.010 ml per 
gram rat weight (Chadwick, 2003). The concentration was worked out using 
the indigenous plant. 
   
 
3.2.2 Metformin 
 
The normal dosage for metformin is 500 or 850mg once daily (Krentz & 
Bailey, 2005).  In the project the dosage was modified to 1000mg per day. 
The tablets were crushed with the aid of pestle and mortar and stored in a 
dried environment. The doses given to the animals were calculated assuming 
that an average adult human weight approximately 75kg. 
 
Each calculated dose was dissolved in 1 ml water and sonicated for 10 
minutes to dissolve the tablet. The medication was given to the rats by 
gavaging on daily basis. 
 
 
3.2.3 Food intake 
 
The LFD rats received rat pellets as they were on a low fat diet. Rats on a 
high fat diet received homemade baked rat cookies that contain a high 
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percentage of fat.  Prolonged elevation of plasma free fatty acids can 
desensitize the insulin secretory response to glucose in vivo, thus inducing a 
beta-cell defect that is similar to that found in type 2 diabetes mellitus (Boden, 
Chen, Ruiz, White, & Rosetti, 1994; Mason, Goh, Tchipashnili, Sandhu, 
Gupta, Lewis,…..Giacca, 1999). Chronic feeding of high fat diet to normal 
rodents reduces proinsulin, glucokinase, and GLUT2 mRNA and suppresses 
glucose insulin secretion (GSIS) (Capito, Hansen, Hedeskov, Islin, & Thams, 
1992; Kim, Iwashita, Tamura, Tokuyama, & Suzuki, 1995).The amount of food 
was not restricted and food and water was provided on daily bases to 3-4 rats 
per cage. 
 
 
3.2.3.1 Preparation of High Fat diet 
Ingredients  
220g of condensed milk 
120g of Wooden Spoon margarine (melted) 
180g of Holsum (melted) 
2000g of rat pellets (in powder form) 
150ml water 
 
All ingredients were mixed into smooth dough and flattened and cut into  
blocks which were baked at 80 o C for 6 hours. 
 
3.2.4 Sacrifice of rats 
Rats were sacrificed after receiving 4 weeks of medication. The rats were 
starved 12-16 hours prior to sacrifice, to ensure the blood glucose is at fasting 
level. On the day of sacrifice the rats were weighed and taken to another 
room to isolate them from the live animals. They were given 1.2ml-1.8 ml of 
ketamine and left for 20 minutes to make them sleep before the sacrifice. 
Figure 3.2.4.1 shows the rat and utensils used for sacrificing. 
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Figure 3.2.4.1 Rat and utensils for sacrificing 
 
3.2.5 Blood collection  
 
3.2.5.1 Pre- sacrifice 
 
Capillary blood was taken from the tail for glucose analysis and then blood 
was also collected using 2ml syringe from the heart before the chest was 
opened. The blood was added to EDTA tubes to prevent blood clots. Five to 
ten millilitres of blood was collected per rat and kept on ice before 
centrifugation at 2000rpm for 20min. Serum was used to determine lipid 
profile and the concentrations of the liver enzymes. 
 
3.2.5.2 Post- sacrifice 
 
Immediately after taking blood, the rat’s chest and abdominal region were 
swabbed with ethanol and opened up. Pancreas, liver, kidney and muscle 
 34
tissue were removed and sliced into small pieces prior to fixing with a 10% 
formalin solution . Urine was collected from the bladder for ketone analyses. 
 
 
3.3 Biochemical Analysis 
3.3.1 Glucose determination 
 
The rats fasted for 12 hours prior to sacrifice, to determine the fasting plasma 
glucose concentration. Capillary blood was taken from the tail for glucose 
determination. A small incision was made on the tail of the rat with the aid of a 
scalpel. A blood droplet was collected and added to an Accu-Chek® glucose 
sensor strip, which was read with a glucometer (Bayer Diagnostics, 2007).  
 
Principle 
Glucose is converted by glucose oxidase into gluconic acid and hydrogen 
peroxide which, in the presence of peroxidase, oxidizes the chromogen (4-
aminoantipyrine/phenol) to a red-coloured compound (Bishop et al., 2010). 
 .  
 
3.3.2 Glucose clearance determination 
The rate of glucose clearance was determined and four to five rats were 
anaesthetised, with an intramuscular injection of ketamine at 3µl/g body 
weight after 12 hours of starvation. The femoral vein was exposed and basal 
blood glucose was determined using an Accu-Chek® glucose strip, which was 
read on a glucometer. One millilitre of 0.9% saline, containing 0.4g/kg glucose 
and 1µCi/500g-deoxy-D-(2.6-H3)    glucose (53Ci/mmol/l specific activity, 
Amersham Bioscience) was injected over 1 min into vemoral vein. Blood 
glucose was measured at 5, 10, 15, 20, 25, 30 and 60 min.  (Chadwick, 
2006).Glucose clearance curve was drawn from the results. 
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3.3.3 Insulin determination 
The insulin was determined using a quantitative Rat Insulin 
Radioimmunoassay (RIA). The primary antibody was raised in guinea pigs 
against highly purified rat insulin.  
 
3.3.3.1 Principle 
A fixed concentration of labelled tracer antigen is incubated with a constant 
dilution of antiserum such that the concentration of antigen binding sites on 
the antibody is limited, for example, only 50 % of the total tracer concentration 
may be bound by antibody. Thus, the unlabelled amount of tracer bound to 
antibody will decrease as the concentration of unlabelled antigen increases. 
This can be measured after separating antibody-bound from free tracer and 
counting one or the other or both fractions. A standard curve is set up with 
increasing concentrations of standard unlabelled antigen and from this curve 
the amount of antigen in the unknown samples can be calculated. The assay 
utilizes 125I labelled insulin and rat insulin antiserum to determine the level of 
rat insulin in serum, plasma or tissue culture media by the double 
antibody/polyethelyne glycol (Linco Research, 2007). Each kit is sufficient to 
run 250 tubes and contains the following reagents: 
 
A. Assay buffer 
0.05M Phosphosaline, pH 7.4, containing 0.025M EDTA, 0.08% 
Sodium  Azide, and 1% RIA Grade Bovine Serum Albumin (BSA). The 
vial contains 40ml and it is ready to be used 
 
B. Rat insulin Antibody 
The vial contains 26ml of Guinea Pig anti-Rat Insulin Serum in Assay 
Buffer and it is ready to be used 
 
C. 125I-Insulin 
125I-Insulin Label, High Performance Liquid Chromatography purified 
(specific activity 367µCi/µg) and lyophilized for stability. Freshly 
iodinated label contains < 5µCi (<185 kBq), calibrated to the first 
Monday of each month. Preparation: the contents on a 27ml vial were 
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lyophilized and were hydrated with entire contents of Label Hydrating 
Buffer. The preparation was left at room temperature for 30 min., with 
occasional mixing. 
 
D. Label Hydrating buffer 
Assay buffer contained Normal Guinea IgG as a carrier. The entire 
content of a 27ml vial was used to hydrate 125I-Insulin and it is ready to 
be used. 
 
E. Rat Insulin Standards 
Purified Rat Insulin Standard Buffer was received in a 2ml vial at the 
following concentration: 0.1, 0.2, 0.5, 1.0, 2.0, 5.0 and 10.0ng/mL. 
F. Quality Controls 1&2 
The vial contained 1ml of Purified Rat Insulin in Assay Buffer and it is 
ready to be used. 
 
G. Precipitating Reagent 
The vial contained  260ml of Goat anti-Guinea Pig IgG Serum, 3% 
PEG and 0.05% Triton X-100 in 0.05M Phosphosaline, 0.025M EDTA 
and 0.05% Sodium Azide. It is ready to be used and must be kept at 
4oC. 
 
 
3.3.3.2 Procedure 
Day One 
1. Pipette 200µL of Assay buffer to the Non- Specific Binding (NSB) tubes (3-
4) and 100µL to Reference (Bo) tubes (5-6) .No buffer is added to tube 7. 
2.  100µL of Standards and Quality Controls were pipetted in duplicate 
3.  100µL of each sample was pipetted in duplicate (Note: smaller volumes of 
sample may be used when insulin concentration is anticipated to be 
elevated or when sample size is limited. Additional buffer should be added 
to compensate for the difference so that the volume is equivalent to 
100µL). 
4. 100µL of hydrated 125I- Insulin was pipetted to all tubes. 
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5.  100µL of Rat Insulin antibody was pipetted to all tubes except Total Count 
tubes (1-2) and NSB tubes (3-4). 
6. The tubes were mixed using a vortex mixer, covered and incubated 
overnight (20-24hours) at 4oC. 
 
Day Two 
7.  1.0 mL of cold (4oC) Precipitating Reagent was added to all tubes except 
Total Count tubes (1-2). 
8. The tubes were mixed using a vortex mixer and incubated for 20 minutes 
at 4oC. 
9. All tubes were centrifuged at 4oC for 20 min at 2000-3000rpm except Total 
Count (1-2). (Note: If less than 2000rpm is used of if slipped pellets have 
been observed in previous runs, the centrifuge must be increased to have 
firm pellet. 
10. Immediately the supernatant of all tubes was decanted except Total Count 
tubes (1-2), the  tubes  were drained and blotted for excess liquid in the 
lips of the tube for at least 15-60 seconds. 
11. The TRI-CARB 2300 TR Liquid Scintillation Analyzer was used to count  
each of the samples for 15 min and the data was recorded.        
 
The normal fasting range is 0.5 – 2.0 ng/ml (Linco Research, 2007). 
   
3.3.4 Liver enzymes 
3.3.4.1 ALT 
Blood was collected in a tube with EDTA anticoagulant and centrifuged at 
2000rpm for 20 min. Serum was used for ALT analysis. Alanine transferase 
(ALT) is a transferase that catalyses the transfer of an amino group from 
alanine to α ketoglutarate with the formation of glutamate and pyruvate. The 
kinetic determination is based upon International Federal of Clinical Chemistry 
(IFCC) recommendations (Bishop et al., 2010). 
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Table 3.3.4.1 Procedure for measuring ALT 
Reagents Control Sample Sample 
Control 100µl - 
Sample - 100µl 
Working reagent 1000µl 1000µl 
 
Reagent 1 contained 
 Tris Buffer, pH 7.8 1000mmol/l 
 L-alanine   500mmol/l 
 LDH   >1000U/L 
 Stabilizers 
 
 
Reagent 2 contained: 
 NADH     0.180mmol/l 
 α ketogluterate   15mmol/l 
 Stabilizers 
 
The working reagents contained 1 volume of reagent 2 to 5 volumes of 
reagent. 
 
Procedure 
 Mix samples and controls and incubate for 1 minute at 37oC. Read initial 
absorbance and start timer. Measure the change in absorbance at 1, 2 and 3 
minutes using spectrophotometer at 340nm. Calculate the concentration using 
the formulae 
At wavelength 340 U/L= ∆ Abs/minx1746 
 
3.3.4.2 AST 
Blood was collected in a tube with EDTA anticoagulant and centrifuged at 
2000rpm for 20minutes. Serum was used for AST analysis. Aspartate 
aminotransferase (AST) is a transferase that catalyses the transfer of an 
amino group between aspartate and α keto acids. The kinetic determination is 
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based upon International Federal of Clinical Chemistry (IFCC) 
recommendations (Bishop et al., 2010). 
 
Table 3.3.4.2 Procedure for measuring AST 
Reagents Control Sample Sample 
Control 100µl - 
Sample - 100µl 
Working reagent 1000µl 1000µl 
 
Reagent 1 contained 
 Tris Buffer,  pH7.8   80mmol/l 
 L-aspartate  200mmol/l 
 MDH   600U/L 
 LDH             900U/L 
 Stabilizers 
 
 
Reagent 2 contained: 
 NADH     0.180mmol/l 
 α ketoglutarate   12mmol/l 
 Stabilizers 
 
 
The working reagents contained 1 volume of reagent 2 to 5 volumes of 
reagent 1 or add 3ml of reagent 2 vial labelled reagent 1. 
 
Procedure 
 Mix your samples and controls and incubate for 1 minute at 37oC. Read initial 
absorbance, and start timer. Measure the change in absorbance at 1, 2 and 3 
minutes using spectrophotometer at 340nm. Calculate the concentration using 
the formulae 
At wavelength 340 U/L=∆Abs/minx1746 
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3.3.5 Lipid Profile 
Plasma in a EDTA tube was used for lipid profile analysis. Total Cholesterol, 
Triglyceride, high density lipoprotein (HDL) were measured and low density 
lipoprotein (LDL) was calculated using the Friedewald equation (Bishop et al., 
2010). 
 
3.3.5.1 Cholesterol 
The total cholesterol is determined after enzymatic hydrolysis followed by an 
oxidation step, the indicator quinoneimine is formed from hydrogen peroxide 
and 4 aminoantipyrine in the presence of phenol and peroxidase which turns 
red, the intensity of which is read at 500nm and is directly proportional to the 
concentration of cholesterol in the sample. The procedure is as follows 
Table 3.3.5.1 Procedure for measuring total cholesterol 
 Reagent Blank Standard Sample 
Standard    - 10µl  
Sample    -    - 10µl 
Working reagent 1000µl 1000µl 1000µl 
 
 
Reagent contains: 
Pipes buffer pH 6.9   50mmol/l 
Phenol    24mmol/l 
Sodium cholate   2.5mmol/l 
Cholesterol esterase  >250U/L 
Cholesterol oxidase   >250U/L 
Peroxidase    >100U/L 
Amino-Antipyrine   0.5mmol/l 
 
The serum Cholesterol Standard concentration: 5.20mmol/l  
 
The working reagent is ready to be used, mix the sample with working reagent 
and incubate at 37oC for 5 minutes. Measure the absorbance of the sample 
and the standard against the reagent blank at 500nm. Next step is to calculate 
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the cholesterol concentration using the following formulae (Bishop et al. 
2010). 
 
Sample concentration= A sample/A standard x concentration of cholesterol 
standard (5.2mmo/l) 
 
3.3.5.2 Triglyceride 
The measurement of serum triglycerides in conjunction with cholesterol is 
useful in detecting certain genetic and other metabolic disorders, as well as in 
characterizing risk of cardiovascular diseases. It is determined after enzymatic 
hydrolysis with lipoprotein lipases. The indicator is a red quinone formed from 
hydrogen peroxide, 4-aminoantipyrine and 4-chlorophenol under the catalytic 
influence of peroxidase. 
 
Table 3.3.5.2 Procedure for measuring triglyceride 
 Reagent Blank Standard Sample 
Standard    - 10µl  
Sample    -    - 10µl 
Working reagent 1000µl 1000µl 1000µl 
 
Reagent contained: 
Pipes buffer, pH 6.9    40mmol/l 
4-chlorophenol    5.0 mmol/l 
Lipoprotein Lipase    1.5U/L 
Peroxidase     0.5U/ml 
Glycerol-3-PO4    1.5U/L 
Glycerol kinase    1.0 U/ml 
4-amino-amptipyrine   0.4mmol/l 
ATP      1.0mmol/L 
Magnesium     5.0mmol/l 
Detergents 
 
 The serum Triglyceride Standard concentration: 2.29mmol/l 
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Procedure 
The working reagent is ready to be used, mix the sample with working reagent 
and incubate at 37oC for 5 minutes. Measure the absorbance of the sample 
and the standard against the reagent blank at 510nm. Next step is to calculate 
the triglyceride concentration using the following formulae (Bishop et al. 
2010). 
Sample triglyceride= A sample/A standard x concentration of triglyceride 
standard (2.29 mmol/l). 
 
3.3.5.3 Serum HDL determination 
The Rongsheng HDL cholesterol diagnostic kit was used for HDL analysis. 
The principle of the method involves the polymer and polyanion in Reagent 1 
reacting with the serum sample and producing a stable protection layer 
around the lipoprotein under the action of surfactant. When Reagent 2 is 
added, elimination reagent releases HDL-cholesterol rapidly, and singly 
catalyzes the HDL- cholesterol reaction under the action of enzymes. The 
intensity of the color is directly proportional to the HDL-CHOL concentration in 
the serum. The procedure is as follows 
 
Table 3.3.5.3 Procedure for measuring HDL cholesterol 
Tube 1 2 3 4 5 
30µl H20 Std Control1 Control 2 Sample 
2.4ml Reagent1 Reagent1 Reagent1 Reagent1 Reagent1 
 Incubate   @37oC for 5minutes  
800µl Reagent 2 Reagent 2 Reagent 2 Reagent 2 Reagent 2 
                                Incubate  @ 37oC for 5 min 
 
  
The HDL cholesterol reagents contained: 
Reagent 1  Good’s Buffer, Phenol, Polyanion, Surfactant 
Reagent 2  Cholesterol Esterase, Cholesterol Oxidase,  
Peroxidase, 4-Amino-antipyrine and Surfactant 
The working reagent was ready to be used, sample was mixed with Reagent  
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1 the incubated at 37oC for 5 minutes, and then Reagent 2 and then incubate 
at 37oC for 5 minutes. It was measured at 546nm against blank. HDL 
concentration was calculated using these formulae 
HDL= standard content x (A2 Serum   -   A1serum/ (A2 standard -
A1standard) 
 
3.3.5.4 Serum LDL determination 
LDL is a treatable risk factor for coronary heart disease. The Friedewald 
calculation is used to estimate LDL cholesterol in routine clinical laboratories. 
The estimated VLDL cholesterol and measured HDL cholesterol are 
subtracted from total serum cholesterol to estimate or derive LDL cholesterol 
(Bishop et al., 2010).  
LDL cholesterol = total cholesterol – HDL-Trig/5 
 
3.3.6 Urine creatinine 
Measurement of creatinine concentration is used to determine sufficiency of 
kidney function and severity of kidney damage and to monitor the progression 
of kidney disease (Bishop et al., 2010).The kinetic Jaffe reaction was used for 
urine creatinine analysis. The principle of the method is that creatinine in 
alkaline solution reacts with picric acid to form a coloured complex. The 
amount of the complex is directly proportional to the creatinine concentration 
in the sample. Urine sample is diluted with distilled water. The procedure is as 
follows: 
 
Table 3.3.6.1 Procedure for measuring urine creatinine 
 Reagent blank Standard Control Sample 
Standard              _      40µl       _  
Control              _       _      40µl  
Sample              _       _       _  40µl 
Working Reagent        1000µl 1000µl 1000µl 1000µl 
 
 
The reagents contain: 
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Reagent 1 
NaOH     300mmol/l 
Na2HPO4.2H2O   15mmol/l 
 
Reagent 2 
Picric Acid    20mmol/l 
Creatinine Standard   177µmol/l 
 
Equal quantities of Reagent 1 and Reagent 2 were mixed to prepare working 
reagent. Working reagents, standards and samples were mixed and 
incubated for 30 seconds at 37ºC. Read initial absorbance A1 and start timer, 
after 3 minutes read A2 of the standard and sample. Calculate the 
concentration using the following formulae   
Urine concentration (mmol/l) = (A2-A1) sample/(A2 –A1)standard X 8.85 
 
 
3.4 Light microscopy analysis 
Upon sacrifice the organs of the rats were removed for histology studies. The 
pancreas, liver and kidneys were placed in 10% buffered formalin solution and 
the samples were fixed overnight to prepare for tissue processing, embedding 
and sectioning.    
 
 
3.4.1 Specimen Fixing 
Formaldehyde-containing fixatives are widely used in histopathology. The 
commercially available solution contains 35-40% gas by weight and it is called 
formalin. In this case 10% buffered formaldehyde was used (Bancroft & 
Stevens, 1996). 
Neutral buffered formaldehyde 
40 % formaldehyde        100ml 
Distilled water        900ml 
Sodium dihydrogen phosphate monohydrate    4g 
Disodium hydrogen phosphate anhydrous    6.5g 
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3.4.2 Tissue processing 
The aim of tissue processing is to embed the tissue in a solid medium firm 
enough to support the tissue and give it sufficient rigidity to enable thin 
sections to be cut and yet soft enough not to damage the knife or tissue. An 
automated tissue processor (Leica TP 1020) was utilized and the process 
took 16-18 hours .The stages involved are: 
i) Dehydration, the specimen move from 70% alcohol to 100% alcohol. 
ii) Clearing, clearite was used 
iii) Impregnation with paraffin wax 
iv) Embedding, tissue was removed and placed in moulds that contained 
paraffin wax (Bancroft & Stevens, 1996). 
 
 
 
3.4.3 Tissue section cutting 
Before the cutting, the clean slides are coated with adhesives to prevent the 
section slipping off during staining. Gelatine was used as an adhesive. 
Sections of 5µm were cut using a rotary microtome and floated in a warm 
water bath (37oC). Sections were mounted on the coated slides and air dried. 
After drying they were stain with a Haemotoxylin and Eosin stain (Cellular 
Pathology Notes, 2010). 
 
3.4.4 Staining Method 
The Haematoxylin and Eosin staining method was used which is widely used 
in histology. 
 
3.4.4.1 Haematoxylin and Eosin staining Method 
Incubate the wax section on the slide at 60oC for 12 minutes and place 
directly into clearite/ xylene for 15 minutes. Rehydrate the sections with 
alcohol starting from 100%, 96%, 90%, 80%, 70%, and 60% for 1 minute each 
then rinse in water for a minute. Place the samples in Haematoxylin for 10 
minutes and rinse in water for 3 minutes. Place the samples in Eosin for 5 
minutes and rinse in water. Dehydrate the samples in alcohol from 60%, 70% 
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80% 90% 96% and 100% for 1 minute each. Place it in clearerite/xylene for 
10 minutes and mount with DPX (Cellular Pathology Notes, 2010). 
 
 
3.5 Immunocytochemistry 
3.5.1 Insulin Immunocytochemistry Method 
Before cutting, the clean slides are coated with adhesives to prevent the 
slipping off of sections during staining; poly-L-lysine was used. Sections of 
4µm were cut using rotary microtome and floated in warm water bath (37oC). 
 
3.5.2 Principle of Vectarstain ABC kit 
The Vectorstain ABC kit is used to demonstrate tissue constituent in situ by 
detecting specific antibody-antigen interactions where antibody has been 
tagged with a visible label. The visual marker may be a fluorescent dye, 
colloidal metal, hapten, radioactive marker or an enzyme.In this project the 
light microscopy an enzyme (peroxidase procedure) was used for the 
localization of a histological significant antigen specific for insulin. This 
technique employs an unlabeled primary antibody, followed by a biotinylated 
secondary antibody and then a performed Avidin and Biotinylated horseradish 
peroxidase complex, a system known as the ABC technique. An anti-mouse 
IgG antibody was used for the localization of the antigen for the insulin 
secreting β-cells of the pancreatic islets (Vector Laboratories, 2007). 
 
3.5.3 Protocol for Paraffin –embedded Sections 
1. Incubate the wax section at 60oC for 12 minutes and place directly into 
clearite/ xylene for 15 minutes. 
2. Rehydrate the sections with alcohol starting from 100%, 96%, 90%, 80%, 
70%, and 60% for 1 minute each then rinse in water for 5 minutes.  
3. Add 2 drops of hydrogen peroxide, leave for 10 minutes and wash with 
buffer. 
4.  Add 2 drops of Blocking serum, leave for 10 minutes and dab off excess. 
5. Add 2 drops of primary antibody and leave for 15minutes and wash with a 
buffer. 
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6. Add 2 drops of secondary antibody, leave for 10 minutes and wash with 
buffer.  
7. Add 2 drops of Vectorstain Elite ABC reagent, leave for 5 minutes and 
wash with buffer. 
8. Add 2 drops of DAB peroxidase substrate leave it for +/- 1 minute and rinse 
it with water. 
9. Put it in Harris Haemotoxylin stain for 1 minute and rinse in water for 3 
minutes. 
10.  Dehydrate the samples in alcohol from 60%, 70%,80%,90%,96% and 
100% for 1 minute each.  
11. Place it in clearite/xylene for 10 minutes and mount with DPX (Vector 
Laboratories, 2007). 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
4.1 Classification of groups 
 
At 11 weeks of age rats on HFD were randomly divided into 4 groups of 6 rats 
to receive treatment. The first group served as a HFD control, the second 
group received plant only, the third group received metformin only, and the 
forth group receive plant + metformin. The gavaging of the rats  commenced 
on the 23 August 2007 when the rats were 11.5 weeks old and continued for 4 
weeks until the 20 September 2007. The rats were gavaged with water for a 
period of 3 days to acclimatize. Drug treatment was commenced from week 
11.5 until week 15.5 .The LFD and HFD groups continue with water gavaging 
for rest of the period. Group 3 received the plant only, group 4 the metformin 
only and group 5 plant + metformin. Weight and growth changes were noted 
during the 4 weeks of treatment. 
 
4.2 Growth and weight gain curves during the study 
 
Before week 11 we had two groups the LFD and HFD, and then the HFD 
group was divided into four groups HFD: control group and 3 test groups; 
plant group, metformin group and plant + metformin group. 
 
Table 4.2 Comparison of average rat weight over the 15weeks 
Groups 1 2 3 4 5 6 7 9  11 12 13 14 15 
LFD 274 315 345 369 407 427 448 486  504 502 511 509 - 
HFD 246 282 310 332 372 391 421 459  500 571 589 582 - 
Plant          500 496 529 546 547 
Met          500 559 572 572 571 
Plant+met          500 530 544 540 535 
                              Before treatment       On treatment 
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Figure 4.2.1 Comparison of average rat weights before treatment 
 
 
Figure 4.2.2 Comparison of average weights during treatment 
 
The rats weighed an averaged of 260g initially. At 11 weeks of age they were 
assigned to different groups and weighed an average of 500g (+/-1.7) before 
starting of medication at week 11.5. Figure 4.2.2 shows the different groups 
indicating that the HFD group had the highest constant weight gain. The 
metformin group had the second highest weight gain and it stabilized and 
started decreasing which support the fact that metformin causes weight loss 
(Chew & Leslie, 2006). The plant group showed an increase in weight from 
week 13 to week 15. Plant + metformin group had the lowest weight again of 
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the treatment groups, initially they showed weight gain but it decreased 
towards the end. 
 
 
Figure 4.2.3 Mean rat weights of all the groups before sacrifice 
 
It is evident that the HFD group had the highest mean weight when compared 
to the other groups, followed by the metformin group, the plant group and the 
plant + metformin group with the LFD group the lowest of them all as 
expected. 
 
4.3 Biochemical analysis 
4.3.1 Fasting blood glucose results 
Table 4.3.1.1 summarises glucometer fasting glucose results 
 
Table 4.3.1.1 Fasting blood glucose results 
 
Glucose 
(mmol/l) 
LFD 
control 
HFD 
control 
Plant Metformin Plant 
+metformin 
 5.3 6.7 5.6 5.3 7.0 
 5.8 4.8 5.1 8.4 5.4 
 5.8 5.1 5.3 5.4 6.1 
 6.1 5.0 6.7 6.6 6.1 
 4.9 5.7 6.1 6.2 6.2 
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 6.1 6.0 5.1 7.3 6.2 
  5.7 5.2   
Mean(mmol/l) 5.7 5.6 5.6 6.5 6.2 
SD 0.476 0.662 0.606 1.183 0.508 
 
 
LFD HFD PLANT MET PLANT+MET
Mean Glucose 5.7 5.6 5.6 6.5 6.2
5.0
5.2
5.4
5.6
5.8
6.0
6.2
6.4
6.6
6.8
(m
m
ol
/l
)
Fasting Glucose Results
 
Figure 4.3.1 Mean fasting glucose results 
 
The normal fasting plasma glucose results is 5.5 -5.7mmol/l (Weitgasser, 
Davalli, & Weir, 1999). The metformin group and the plant + met group had 
raised mean fasting glucose results and all the other groups had normal 
glucose results.  
 
4.3.2 Blood Glucose Clearance 
The rate of glucose clearance was slower in the HFD group as compared to 
the other groups. The slower rate of glucose clearance over an hour in the 
HFD group as compared to the rapid rate of clearance in the LFD group and it 
indicates insulin resistance in HFD group (Chadwick, 2006). The plant, 
metformin and plant + metformin groups showed increased glucose 
clearance. Table 4.3.2.1 shows the mean glucose clearance results for all the 
groups. 
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Table 4.3.2.1 Glucose clearance results  
 
   
     
Glucose 
Clearance 
(minutes) 
 
 
0 min 
 
 
5min 
 
 
10min 
 
 
15min 
 
 
20min
 
 
 
25min 
 
 
 
30min 
 
 
 
60min 
LFD 5.1 13.1 10.0 7.0 6.8 5.8 6.0 5.6 
HFD 5.5 13.4 10.9 8.2 7.7 6.4 6.0 5.4 
Plant 5.5 12.5 10.1 8.6 7.7 6.0 6.3 5.5 
Metformin 5.3 12.8 9.6 7.8 6.6 5.7 5.7 5.1 
Plant+Met 5.8 12.3 10.0 8.0 6.5       5.5 5.9 5.8 
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Figure 4.3.2.1 Glucose clearance curve 
 
4.3.3 Blood Insulin determination 
The quantitative Rat insulin Radioimmunoassay was used for insulin 
determination. The average duplicate counts for Total Count Tubes (1-2), 
NSB tubes (3-4), Total binding tubes reference, Bo (5-6), and all duplicate 
standards and samples were calculated. The average NSB count was 
subtracted from each average count except for Total Count. Tracer bound, 
total binding (%B/Bo) for each standard and sample were also calculated. the 
 53
known concentration of the standards on the log- log graph paper (Figure 
4.3.3.1). Determination of insulin (ng/ml) of unknown samples and controls 
was done using by using interpolation of reference curve. 
 
Figure 4.3.3.1 The log-log standard curve for insulin determination 
Table 4.3.3.1 Summary of insulin levels in the different groups 
Insulin (ng/ml) LFD HFD Plant   Metformin Plant + Met 
 0.747 2.378 0.629 2.357 2.87 
 0.382 0.548 0.617 6.123 3.61 
 0.963 0.878 0.912 1.079 3.89 
 0.989 0.831 2.267 1.173 2.65 
 0.381 2.288 0.828 1.485 1.09 
 0.538 0.873 1.034 0.353  
  0.994 0.653   
Mean 0.7 1.3 1.0 2.1 2.8 
SD 0.275 0.749 0.584 2.078 1.110 
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This is indicated in Table 4.3.3.1 and a graph was plotted of %B/Bo against 
 
Figure 4.3.3.2 Mean insulin results 
 
The insulin results of the HFD group were increased but still within the range 
when compared to the LFD group due to insulin resistance of these rats. The 
plant group showed normal insulin levels, indicating that in spite of insulin 
resistance and the fact that they were on a high fat diet, normal glucose and 
insulin were maintained. The metformin group had slightly higher insulin 
results even higher than the HFD group, which is caused by high fat diet 
undergoing β cell aptosis due to increase cellular breakdown leading to less 
insulin produced and secreted (Chadwick, Roux, Van der Venter, Louw, & 
Willem, 2007). The plant+ metformin group had a very high insulin results; 
hyperinsulinemia has been noted and fasting glucose is normal. An outlier in 
the results was noted, and it was not included in the data analysis. 
 
4.3.4 Blood Lipid profile determination 
4.3.4.1Total serum cholesterol determination 
Table 4.3.4.1 Summary of total serum cholesterol for all the rat groups 
Cholesterol 
(mmo/l) 
LFD HFD Plant Metformin Plant + 
Met 
 1.2 1.2 1.4 1.2 1.2 
 1.2 1.2 1.2 1.2 1.2 
 55
 1.3 1.3 1.1 1.1 1.3 
 1.0 1.2 1.4 1.5 1.5 
 1.1 1.4 1.1 1.5 1.6 
 1.2 1.1 1.2 1.3 1.1 
  1.2 1.2   
Mean 1.2 1.2 1.2 1.3 1.3 
SD 0.103 0.095 0.125 0.167 0.194 
 
 
The reference range for cholesterol is 1.0 -2.2 mmol/L for 8-16 weeks old rats 
(Bachorik & Ross, 1995; Giknis & Charles, 2008) All the groups had normal 
total serum cholesterol. The plant+ metformin group had the highest mean 
total cholesterol, although it was still within normal range. Figure 4.3.4.1 
shows the means of the different groups. 
 
 
Figure 4.3.4.1 Mean serum cholesterol results in the different groups 
 
 
4.3.4.2 Serum Triglyceride determination 
In Table 4.3.4.2.1 serum triglyceride results are summarised. 
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Table 4.3.4.2.1 Summary of serum triglyceride for all the rat groups 
Triglyceride 
(mmol/l) 
LFD HFD Plant Metfomin Plant +Met 
 1.1 1.0 1.3 1.2 1.2 
 1.3 1.4 1.1 1.5 1.0 
 1.3 1.1 1.1 1.2 1.2 
 1.3 1.2 1.2 1.3 1.4 
 1.2 1.2 1.2 1.3 1.5 
 1.1 1.5 1.6 1.8 1.8 
  1.2 1.4   
Mean 1.2 1.2 1.3 1.4 1.4 
SD 0.098 0.170 0.180 0.231 0.281 
 
The reference range for serum triglyceride of rats 8-16 weeks old is 0.23 – 1.3 
mmol/L (Bachorik & Ross, 1995; Giknis & Charles 2008). All the groups 
showed normal serum triglyceride except metformin and plant +metformin 
group which were slightly increased. Both of these two groups were not 
significantly high. Figure 4.3.4.2 shows the mean of the different groups. The 
metformin group has the highest mean. 
 
Figure 4.3.4.2 Mean serum triglyceride results in the different groups 
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4.3.4.3. Serum HDL determination 
In Table 4.3.4.3 serum HDL results have been summarised 
 
Table 4.3.4.3 Summary of serum HDL cholesterol for all rat groups 
HDL cholesterol 
(mmo/l) 
LFD HFD Plant Metformin Plant+Met 
 0.34 0.64 0.35 0.39 0.37 
 0.38 0.43 0.29 0.33 0.29 
 0.32 0.41 0.28 0.38 0.41 
 0.28 0.43 0.35 0.49 0.48 
 0.28 0.35 0.25 0.49 0.38 
 0.40 0.34 0.39 0.52 0.38 
  0.34 0.38   
Mean 0.3 0.4 0.3 0.4 0.4 
SD 0.050 0.105 0.054 0.080 0.061 
 
 
 
Figure 4.3.4.3 Mean serum HDL cholesterol results of the different groups 
 
Normal reference ranges for HDL cholesterol are 0.874 – 1.374 mmol/l. All rat 
HDL cholesterol values obtained were below the normal range and it could 
not provide information about the test groups metformin, plant, plant+ 
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metformin drug activity. No significant differences amongst the groups were 
observed (Akapnabiatu, Umoh, Udosen, & Edet, 2005). 
 
4.3.4.4 Serum LDL determination 
In Table 4.3.4.4 LDL results calculated using Friedewald equation are shown. 
Table 4.3.4.4 Summary of serum LDL cholesterol for all rat groups 
LDL cholesterol LFD HFD Plant Metformin Plant+Met 
 0.64 0.36 0.79 0.57 0.59 
 0.56 0.49 0.69 0.57 0.71 
 0.72 0.67 0.60 0.48 0.65 
 0.46 0.53 0.77 0.75 0.74 
 0.58 0.81 0.61 0.75 0.92 
 0.56 0.46 0.55 0.42 0.36 
  0.51 0.50   
Mean 0.6 0.6 0.6 0.6 0.7 
SD 0.087 0.148 0.109 0.136 0.185 
 
 
 
Figure 4.3.4.4    Mean serum LDL cholesterol of the different groups 
 
The normal reference range for LDL cholesterol is 0.386 – 0.626 mmol/l. All 
the groups were normal except the plant+ metformin group which was slightly 
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higher (Akapnabiatu et al., 2005).  In Table 4.3.4.5 the lipid profile results are 
summarised. 
Table 4.3.4.5 Summary of Lipid profile Results: Total chol, Trig, HDL and LDL 
 
Group Total 
Chol 
mmol/l 
Mean Trig 
mmol
/l 
Mean HDL Mean LDL Mean 
LFD 
Control 
1.2  1.1  0.34  0.64  
 1.2  1.3  0.38  0.56  
 1.3  1.3  0.32  0.72  
 1.0  1.3  0.28  0.46  
 1.1  1.2  0.28  0.58  
 1.2  1.1  0.4  0.56  
  1.2  1.2  0.3  0.6 
HFD 
Control 
1.2  1.0  0.64  0.36  
 1.2  1.4  0.43  0.49  
 1.3  1.1  0.41  0.67  
 1.2  1.2  0.43  0.53  
 1.4  1.2  0.35  0.81  
 1.1  1.5  0.34  0.46  
 1.2  1.2  0.34  0.51  
  1.2  1.2  0.4  0.6 
Plant 1.4  1.3  0.35  0.79  
 1.2  1.1  0.29  0.69  
 1.1  1.1  0.28  0.60  
 1.4  1.2  0.35  0.77  
 1.1  1.2  0.25  0.61  
 1.2  1.6  0.39  0.55  
 1.2  1.4  0.38  0.50  
  1.2  1.3  0.3  0.6 
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Met 1.2  1.2  0.39  0.57  
 1.2  1.5  0.33  0.57  
 1.1  1.2  0.38  0.48  
 1.5  1.3  0.49  0.75  
 1.5  1.3  0.49  0.75  
 1.3  1.8  0.52  0.42  
  1.3  1.4  0.4  0.6 
Plant + 
Met 
1.2  1.2  0.37  0.59  
 1.2  1.0  0.29  0.71  
 1.3  1.2  0.41  0.65  
 1.5  1.4  0.48  0.74  
 1.6  1.5  0.38  0.92  
 1.1  1.8  0.38  0.36  
  1.3  1.4  0.4  0.7 
 
 
4.3.5 Liver Enzymes determination 
Individuals with type II diabetes have higher incidence of liver function test 
abnormalities than individuals who do not have diabetes. Mild chronic 
elevations of transaminases often reflect underlying insulin resistance.   
 
4.3.5.1Serum ALT determination 
ALT is a risk factor for type II diabetes and indicates a potential role of 
increased hepatic gluconeogenesis and or inflammation. Antidiabetics have 
been shown to decrease ALT as glucose results are kept normal (Harris, 
2005).Table 4.3.5.1 summarises ALT results. 
 
Table 4.3.5.1 Serum ALT Results for all the rat groups 
ALT (U/L) LFD HFD Plant Metformin Plant+ Met 
 20.0 17.0 48.0 42.0 16.0 
 17.5 17.0 21.0 28.0 37.0 
 20.4 23.0 47.0 43.0 61.0 
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 27.0 19.0 15.0 44.0 45.0 
 18.0 13.0 32.0 37.0 15.0 
 17.0 29.0 20.0 33.0 17.0 
  20 30.2   
Mean 20.0 19.7 30.5 37.83 31.8 
SD 3.70 5.12 13.05 6.37 18.99 
 
The reference range for serum ALT for rats 8-16 weeks is 18-45 U/L 
(Bachorik & Ross, 1995; Giknis & Charles, 2008).The entire population had 
normal ALT results. Figure 4.3.5.1 shows the mean serum ALT results of the 
different groups. 
 
Figure 4.3.5.1 Mean serum ALT Results 
 
4.3.5.2 Serum AST determination 
Table 4.3.5.2.1 Serum AST Results for all the rat groups 
AST (U/L) LFD HFD Plant Metformin Plant+Met 
 18.0 64.6 81.0 65.0 81.0 
 6.0 30.6 144.0 52.0 93.0 
 40.0 41.1 70.0 79.0 77.9 
 39.9 41.0 39.0 57.0 88.3 
 30.3 35.2 44.0 28.0 62.0 
 47.7 41.0 76.0 61.0 65.0 
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  34.0 75.6   
Mean 30.3 41.1 75.7 57.0 77.9 
SD 15.69 11.1 34.3 16.91 12.37 
 
The referance range for AST results  is between 56 - 138  U/L(Tucker , 1997). 
All the results were less than the referance range. The LFD  group and the 
HFD group were less than 56 U/L and the plant + metformin group was the 
highest but still within the normal range.Figure 4.3.5.2 summerises the mean 
of the AST results for the different groups. 
 
Figure 4.3.5.2.1 Mean serum AST results for the different groups 
 
4.3.6 Urine Creatinine results 
Measurement of creatinine is used to determine sufficiency of kidney function 
and the severity of kidney damage and to monitor progression of kidney 
damage. It can be measured in plasma, serum and urine (Kaplan, Jack, 
Opheim, Toivola, & Lyon, 1995; Bishop et al., 2010). 
 
Table 4.3.6.1 Summary of Urine creatinine for the three test groups 
Urine Creatinine 
(mmol/day) 
Plant Metformin Plant 
+Met 
 19.0 4.8 8.2 
 7.2 5.8 4.8 
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 5.1 3.4 12.3 
 8.9 12.9 12.9 
 3.1 24.2 3.4 
 4.8 10.9 12.9 
 7.9   
Mean 8.0 10.3 9.1 
SD 5.24 7.73 4.26 
 
 
Figure 4.3.6.1 Mean of the Urine creatinine for the test groups 
 
The reference ranges of urine creatinine is 5.3 – 15.9 mmol/day (Bishop et al., 
2010). All the test groups were normal when compared to the reference 
range. The metformin group was slightly higher when compared to the other 
groups; increased creatinine is significant of kidney damage. 
  
 
 
4.4 Light microscopy analysis 
The data for light microscopy was analysed and summarised, focusing on the 
abnormalities and comparing the different groups. 
 
4.4.1 Pancreas 
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The pancreas is a mixed exocrine-endocrine gland. The exocrine portion of 
secretory units forms the largest volume; the ducts, vessels and connective 
tissue; and the endocrine tissue the Islets of Langehans. The Islets of 
Langerhans are variable in size but usually ovoid in shape, it one of the 
unique features (Kerr, 1999). 
 
4.4.1.1 LFD group 
The islets varied in size from small to big islets and dominated by big islets 
and normal round shape. The average count of islets per slide was 12. Figure 
4.4.1.1 shows an example of a histological section of rat pancreas for LFD 
group. 
 
 
  
Figure 4.4.1.1 An example of a histological section of rat pancreas for LFD 
group stained using H&E under X40 magnification 
 
 
4.4.1.2 HFD group 
The islets were dominated by medium to small islets and normal round shape. 
The average count of islets per slide was 11. Figure 4.4.1.2 shows an 
example of a histological section of a rat pancreas for HFD group. 
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Figure 4.4.1.2 An example of histological section of rat pancreas for HFD 
group stained using H&E under X40 magnification 
 
 
4.4.1.3 Plant group 
The dominating islets were very big and abnormal shapes were present. 
Pancreatic hypertrophy and hyperplasia were observed. The average count of 
islets per slide was 12. Figure 4.4.1.3 shows an example of histological 
section of rat pancreas for the plant group. 
 
Figure 4.4.1.3 An example of histological section of rat pancreas for the plant 
group stained using H&E under X40 magnification 
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4.4.1.4 Metformin group 
The islets were small to big in size and normal round shape. The average 
count of islet per slide was 11. Figure 4.4.1.4 shows an example of 
histological section of rat pancreas for the metformin group. 
 
 
Figure 4.4.1.4 An example of histological section of rat pancreas for the 
Metformin group stained using H&E under X40 magnification 
 
4.4.1.5 Plant + Metformin 
 The islets sizes were medium to large and the shape was normal. Focal 
necrosis was noted in the pancreas. The average count was 12 islets per 
slide. Figure 4.4.1.5 shows an example of histological section of rat pancreas 
for plant+metformin group. 
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Figure 4.4.1.5 An example of histological section of rat pancreas for plant + 
metformin group stained using H&E under X40 magnification 
 
 
Table 4.4.1.5 Comparison of the pancreatic islets for the different rat groups  
Group Shape of islets Size of islets Mean of islets per 
slide 
LFD normal Small to large 11.7 
HFD normal Small to medium 10.7 
Plant Abnormal shape Medium to large 12.4 
Metformin normal Small to large 11.3 
Plant+ metformin normal Medium to large 12.3 
 
Table 4.4.1.5 summarizes the differences and similarities of the different 
groups. Figure 4.4.1.6 shows the mean of pancreatic islets per slide for the 
different groups. 
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Figure 4.4.1.6 Mean of Pancreatic islets per slide for the different groups 
 
 
4.4.2 Liver 
The classic hepatic lobule has a central vein from the liver parenchymal cells, 
termed hepatocytes radiate outward like spokes of wheel. Hepatocytes are 
arranged into irregular, branching, and interconnected plates termed hepatic 
cords. They are polyhedral in form and have central nucleus one or more 
prominent nucleoli (Tallitsch & Guastaferri, 2009). The liver pathology results 
were verified by Dr J Erasmus (personal communication, December 2, 2011). 
 
4.4.2.1 LFD group 
 The hepatocytes were polyhedral in shape showing an eosinophillic and 
basophllic nucleus. The nucleus was the same size and uniform in shape, no 
abnormalities noted. Figure 4.4.2.1 shows an example of histological section 
of rat liver for LFD group. 
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Figure 4.4.2.1 An example of histology section of rat liver for LFD group  
 stained using H&E X40 magnification 
 
4.4.2.2 HFD group 
Slight cytoplasmic abnormalities were noted, vacuoles in the hepatocytes 
were observed. Slight focal steatosis was present because of high fat diet 
(microvesicular) due to high lipid content (Zou, Li, Lu, Wang, Ge, 
Huang,….Wang, 2006; Zhou, Zhou, Zhang, Tang, Guang, Ying,….Li, 2008). 
Figure 4.4.2.2 shows an example of the histological section for the HFD 
group. 
 
Figure 4.4.2.2 An example of histological section of rat for the HFD group  
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 stained using H&E X40 magnification 
 
4.4.2.3 Plant 
The rat liver of the plant group was relatively normal, no abnormalities were 
noted. Figure 4.4.2.3.1 shows an example of histological section for the rat 
liver for the plant group. 
 
 
Figure 4.4.2.3 An example of histological section of rat liver for the plant group 
 stained using H&E X40 magnification  
 
 
4.4.2.4 Metformin 
There were abnormalities noted in the metformin group. Signs of inflammation 
were noted, moderate focal perivenular inflammation associated with chronic 
inflammation was observed which can be drug induced (Graeves, 
2000).Figure 4.4.2.4 shows an example of the histological section of the rat 
liver for the metformin group. 
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Figure 4.4.2.4 An example of the histological section for the rat liver for the 
metformin group stained using H&E X40 magnification 
 
 
 
4.4.2.5 Plant + Metformin 
Slight focal perivenular inflammation was noted in the plant + metformin 
group. Figure 4.4.2.5 shows an example the rat histological section of the rat 
liver for the plant +metformin group. 
 
Figure 4.4.2.5 An example of the histological section of the rat liver for plant + 
metformin group stained using H&E X40 magnification  
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4.4.3 Kidney 
 
The clinical manifestations of diabetic nephropathy are strongly related to the 
structural changes, especially with the degree of mesangial expansion in both 
Type I and Type II diabetes (Zhang et al., 1997; Fioretto & Mauer, 2007). 
Previous studies using light and electron microscopic morphometric analysis 
have described the renal structural changes and functional relationships in 
diabetic nephropathy (Fioretto & Mauer, 2007). Many therapeutic and 
diagnostic agents used in humans have the potential to cause renal damage. 
In preclinical toxicity studies, renal changes are changes particularly liable to 
occur because of the high doses given and the fact that the kidneys eliminate 
many drugs and their matabolites. Glomerulorosclerosis which is a form 
chronic glomerular disease is also observed in toxicity studies of rats and is 
one of the findings that should be reported (Greaves, 2000). The main 
structural and functional unit of the kidney is the nephron and it is composed 
of the glomerulus and the renal tubule. The different parts of the renal tubule 
were identified using Haematoxylin and eosin stain. The kidney pathology 
results were confirmed by Dr J Erasmus (personal communication, December 
2, 2011). 
 
4.4.3.1 LFD group 
 The kidney sections showed normal afferent and efferent arteriole and the 
epithelial cells attached to the basement membrane of the glomerulus stained 
eosiniphillic with basophilic vesicular nuclei (Macfarlene, Reid, & Callander, 
2000). Figure 4.4.3.1 shows the histological section of the rat kidney for the 
LFD group. 
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Figure 4.4.3.1 An example of histological section of rat kidney for LFD group  
 stained using H&E X40 magnification  
 
 
4.4.3.2 HFD Group 
The glomerulus was normal and it looked more like the LFD group. Figure 
4.4.3.2 illustrates the histological section of rat kidney for the HFD group. 
 
 
Figure 4.4.3.2 An example of histological section of rat kidney for HFD group  
 stained using H&E X40 magnification  
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4.4.3.3 Plant 
The glomerulus was relatively normal and there were no abnormalities 
observed. Figure 4.4.3.3 illustrates an example of histological section of rat 
kidney for the plant group. 
 
 
Figure 4.4.3.3 An example of histological section of rat kidney for plant group  
 stained using H&E X40 magnification  
 
4.4.3.4 Metformin 
The metformin group had relatively normal glomerulus and there were no 
abnormalities observed. Figure 4.4.3.4 illustrates an example of the 
histological section of rat kidney for the metformin group. 
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Figure 4.4.3.4 An example of histological section for the rat kidney for 
metformin group stained using H&E X40 magnification  
 
 
4.4.3.5 Plant + metformin 
The kidney showed normal glomerular space. Figure 4.4.3.5 illustrates the 
histological section of rat kidney for the plant + metformin group. 
 
 
Figure 4.4.3.5 An example histology section of rat kidney for plant + metformin 
group  stained using H&E X40 magnification 
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4.5 Immunocytochemistry (ICC) analysis of pancreatic islets 
4.5.1 LFD group 
 The concentration of brown stained β cells is directly proportional to insulin 
present (Graeves, 2000; Van Gend, 2008).  In Figure 4.5.1DAB staining is 
used to illustrate concentration of insulin secreted by the pancreatic β islets. 
 
 
Figure 4.5.1 Immunocytochemistry DAB staining (x40) shows pancreatic islets 
of LFD group 
 
4.5.2 HFD group 
The intensity of DAB staining in this group as illustrated by Figure 4.5.2 was 
more when compared to the LFD group. 
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Figure 4.5.2 Immunocytochemistry DAB staining (x40) shows pancreatic islets 
of HFD group 
 
4.5.3 Plant group 
The intensity of DAB staining in this group as illustrated by Figure 4.5.3 was 
less than HFD group but more than LFD group. 
 
 
 
  
Figure 4.5.3 Immunocytochemistry DAB staining(X40) 
 shows pancreatic islets of plant group 
 
4.5.4 Metformin group 
As illustrated by Figure 4.5.4 the intensity of metformin group was stronger 
than the plant group. It correlates with the mean insulin results. 
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Figure 4.5.4 Immunocytochemistry DAB staining (x40) shows pancreatic islets 
of Metformin group 
 
4.5.5 Plant + metformin group 
As illustrated in Figure 4.5.1.5 the intensity of staining was stronger in this 
group and it varied. It correlates with the increased mean insulin in this group 
and the drug treatment given to this group has affected the secretion of insulin 
by pancreatic β cells. 
 
  
 Figure 4.5.5 Immunocytochemistry DAB staining (x40) shows pancreatic 
islets of plant +metformin group 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
Diabetes mellitus is a common chronic disorder and represents a serious 
health challenge. The increase in the prevalence of type II diabetes is closely 
linked to the upsurge in obesity. The proliferation of cheap, highly palatable, 
high fat, instant fast and prepacked foods is assumed to contribute to over 
consumption and to divest consumers of control over preparation of their 
own foods. Studies have revealed that high fat diet promotes hyperglycemia 
and whole body insulin resistance and numerous researchers have 
examined their effects on certain tissues as well as insulin signal 
transduction (Buettner et al., 2006). 
 
Despite the technical advances in diagnosis and therapy of diabetes many 
people still use alternative forms of therapy due to the cost, side effects, 
traditional reasons and religion. Some of the people use the conventional 
medication together with the alternative therapy without informing their 
doctor. A single medication can be effective for healing a particular disease; it 
can also be more effective, when combined with another alternative therapy. 
In other cases, when combined it can be less effective or even not effective at 
all and cause pathological changes. Most South Africans are taking 
conventional treatment together with the alternative treatment without knowing 
the synergistic and antagonistic effects (Egede et al., 2002; Chadwick, 2003).  
 
Studies have been conducted by researchers to investigate metabolic effects 
of the different types of antidiabetics on human and rats. Chadwick (2006) has 
established antidiabetic effects of Sutherlandia frutescens in high fat diet 
induced diabetic Wistar rats. Metformin, a biguanide, is the drug of preference 
in the presence of obesity and insulin resistance (Atabek & Pirgon, 2008; 
Desilets et al., 2008). Like all other drugs it has side effects. The 
morphological alteration and biochemical changes caused by the combination 
of metformin and Sutherlandia frutescens have never been explored.  
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This study was an innovative investigation, since it was the first time that 
metformin and Sutherlandia frutescens were administered to rats on a 
chronic basis to investigate pathological changes. The choice of a plant 
extract administered was based on a study “Antidiabetic effect of 
Sutherlandia frutescens in Wistar rats fed diabetogia diet” by Chadwick, 
(2003). The drug interaction of the co-treatment of metformin and 
Sutherlandia frutescens and the tissue damage caused by this was not 
known. To date no other study has investigated this drug combination, and 
also included histopathology and immunocytochemical analysis. 
 
The rats were fed a high fat diet for 11 weeks to induce diabetes mellitus, 
and started the treatment at 11 ½ weeks for 4 weeks. Some of the rats were 
obese. The gaining of weight during the experiment was observed; the HFD 
control group had the highest weight, which was expected because they 
were on the high fat diet and no medication. The metformin group was the 
second highest and then it stabilized and started dropping. This was 
expected as metformin causes loss of weight (Chew & Leslie, 2006). The 
plant group is the third highest and shows increase of weight at the end, 
which is a concern because gaining of weight is associated with insulin 
resistance. The weight gain may be due to the fact that they were still on a 
high fat diet. Management of diabetes mellitus include other factors that 
include diet as well. The plant +metformin group showed the lowest weight 
gain of the experimental groups, which is the ideal for diabetes mellitus 
management. 
 
Blood was collected for biochemical analysis, fasting glucose was performed 
and it was normal for all the groups except for the metformin group and plant 
+ metformin group which were raised and hyperglycemia was noted. The 
reference range for the whole blood fasting glucose is 5.5 – 5.7 mmol/l. The 
metformin group was 6.5mmo/l and plant + metformin group was 6.2 mmol/l. 
The glucose clearance of the plant group, metformin group and plant + 
metformin group was faster or increased as compared to the HFD group 
which showed improved insulin resistance.  The HFD group insulin group 
was increased but normal as compared to the LFD group due to insulin 
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resistance. The plant group showed normal insulin levels, indicating that in 
spite of insulin resistance and the fact that they were still on a high fat diet, 
normal glucose and insulin were maintained. The metformin group had slightly 
raised insulin levels even higher than the HFD group, which is induced by 
high fat diet undergoing β pancreatic cell to undergo aptosis due to increased 
cellular breakdown leading to less insulin produced and secreted (Chadwick, 
et al., 2007). The plant+ metformin group has very high insulin results; 
hyperinsulinemia was noted and fasting glucose was also high. This is shown 
in Figure 4.3.3.1. 
 
There was no significant differences in the cholesterol results, all the rats 
were normal. The triglyceride results indicated that all the rats were normal 
except for metformin and plant + metformin groups that were slightly 
increased. The results were not expected because metformin also acts in an 
insulin dependent manner to suppress oxidation of fatty acids and reduce 
triglyceride levels in patients with hypertriglyceridemia (Krentz and Bailey, 
2005). The HDL cholesterol results were all low and could not provide 
information for the test groups, there was no significant difference in all the 
groups. The LDL cholesterol results of all the groups were normal except for 
plant + metformin group which was slightly high. There were no significant 
differences in all the groups. 
 
The ALT results were all normal in the entire population. Although the 
metformin and plant + metformin group were normal they were significantly 
increased as compared to the LFD and HFD control groups. Individuals with 
type II diabetes have higher incidence of liver function test abnormalities than 
individuals who do not have diabetes. Mild chronic elevations of 
transaminases often reflect underlying insulin resistance. Increased ALT is a 
risk factor predictor for type II diabetes and indicates a potential role of 
increased hepatic gluconeogenesis and or inflammation (Harris, 2005). To 
support this, the histology results of the two groups showed focal perivenular 
inflammation associated with chronic inflammation  which can also be drug 
induced (Graeves, 2000).Figure 4.4.2.4 and Figure 4.4.2.4 illustrate the rat 
liver histology for the metformin  and plant + metformin groups. The AST 
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results were all normal in the entire population with plant + metformin group 
the highest. 
 
Urine creatinine was performed to evaluate renal damage which may be 
caused by oxidative stress in the pathogenesis of nephropathy (Zhang et al., 
1997). All the test groups were normal when compared to the reference 
range. The metformin group was slightly higher as compared to the other 
groups; increased creatinine is significant of kidney damage. The histology 
results were all normal for all the groups, therefore there was no kidney 
damage observed.  
 
Various types or degrees of islet cell hyperplasia occur in laboratory animals 
either spontaneously with advancing age or following administration of 
chemicals. Large islets were also noted particularly common in genetically 
obese strains and strains which develop type II diabetes (Graeves, 2000;  
Rosmalen, Pigmans, Kerseboom, Drexhage, Leenen, & Homo-Delarche, 
2001). Slight hypertrophy and hyperplasia were noted in the plant group. 
None of these morphological changes were present in the control group. 
Slight pancreatic necrosis was noted in the plant + metformin group which 
was not present on the control groups. Figure 5.1 illustrates the different 
pancreatic tissue. 
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Figure 5.1 Comparison of the pancreatic tissue in all the groups 
H&E X40 magnification. A- LFD group, B- HFD group, C-Plant group, D-
Metformin group and E-plant +metformin group. 
 
 
Slight focal steatosis was noted in the HFD control group which was not 
present on the LFD group because of high fat diet (microvesicular) due to high 
lipid content. The diet had a negative effect on the liver.  In the metformin 
group, moderate perivenular inflammation was observed, which can be 
induced by chronic drug exposure. The plant + metformin group had very 
slight perivenular inflammation noted. The plant group was relatively normal 
and looked almost like the LFD control group. Figure 5.2 illustrates the 
comparison between the different groups. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
E 
A B 
 C D 
 84
 
 
 
 
 
 
 
Figure 5.2 Comparison of the liver tissue in all the groups 
H&E X40 magnification. A - LFD group, B – HFD group, C –Plant group, D – 
Metformin group, E – Plant + Metformin 
 
 
Previous studies using light and electron microscopic morphometric analysis 
have described the renal structural changes and functional relationships in 
diabetic nephropathy (Fioretto & Mauer, 2007). Many therapeutic and 
diagnostic agents used in humans have the potential to cause renal damage. 
All the groups were normal, like the LFD group, which is supported by the 
normal urine creatinine in the test group. Diabetic nephropathy is a long term 
complication of diabetes mellitus, if the rats lived longer and were on 
medication for longer than 4 weeks, the possibility could occur of renal 
damage. Figure 5.3 illustrates the comparison of kidney tissue for the different 
groups. 
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Figure 5.3 Comparison of the kidney tissue in all the groups 
H&E X40 magnification. A- LFD group, B- HFD group, C-Plant group, D-
Metformin group and E-plant +metformin group. 
 
An immunocytochemical stain was performed to reveal the concentration of 
brown stained β cells which is directly proportional to insulin present. In Figure 
5.4 DAB staining is used to illustrate concentration of insulin secreted by the 
pancreatic β islets. The plant + metformin group was the darkest of the entire 
group, followed by the metformin group, then HFD group, plant group and the 
LFD group, which were supported by blood insulin results. 
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Figure 5.4 Comparison of Immunocytochemistry DAB staining (x40) shows 
pancreatic islets of all the rat groups. A- LFD group, B- HFD group, C-Plant 
group, D-Metformin group and E-plant +metformin group. 
 
 
In conclusion insulin resistance was induced by using a high fat diet, glucose 
clearance test confirm that. Unfortunately the morphological changes were not 
an exact match of biochemical findings due to the short term of the medication 
period. There was tissue damage present in the liver caused by chronic use of 
metformin. In conclusion metformin use is potentially dangerous. 
 
The plant was found to prevent the liver damages caused by high fat diet, 
present in the other groups. This is supported by the research done on 
Sutherlandia frutescens as a complimentary antidiabetic medication 
(Chadwick, 2003). Hypertrophy and hyperplasia of pancreas in the plant 
group was also noted, which has a   negative effect on the production of 
insulin by pancreas. 
 
The plant + metformin group co- treatment was better in managing 
hyperglycemia, liver damages were minimal and also weight control was 
better when compared to metformin alone. Pancreatic necrosis and 
hyperinsulinemia were noted which is a negative effect. It is difficult to 
conclude whether this co-treatment is synergistic or antagonistic because it 
has advantages and disadvantages. The potential for traditional medicine and 
conventional medicine to interact unfavourably may depend on the mixture 
and concentration. In this project metformin was adjusted to 1000mg per day 
instead of 850mg. 
 
E 
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A suggestion for future studies is that rats should receive medication for a 
prolonged period. The blood picture, namely glucose, insulin, lipid profile and 
liver enzymes as well as histology will be conclusive. Taking all this into 
consideration, the researcher will be able to determine whether the co-
treatment of plant + metformin is synergistic or antagonistic. 
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